Multifunctional fusion proteins and uses thereof
Patent Information
- Application Number
- JP2021539880
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-01-07
- Filing Date
- 2020-01-07
- Publication Date
- 2024-11-20
- Estimated Expiration
- 2040-01-07
Smart Images

Figure 0007587505000035 
Figure 0007587505000036 
Figure 0007587505000037
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority under 35 U.S.C. §119(e) to U.S. Provisional Patent Application No. 62 / 789,212, filed January 7, 2019, the entirety of which is incorporated herein by reference. [Background technology]
[0002] Several pathways control the survival of infected and cancer cells, as well as the activation or suppression of immune system cells such as T cells and natural killer (NK) cells. One pathway that delivers costimulatory and inhibitory second signals to T cells is represented by the programmed death 1 (PD-1, also known as CD279) receptor and its ligands PD-L1 (B7-H1; CD274) and PD-L2 (B7-DC; CD273). PD-1 is a CD28 / CTL4 family member that is expressed on activated but not resting T cells (Nishimura et al., 1996, Int. Immunol. 8:773). Binding of the ligand to PD-1 establishes an inhibitory signal that leads to decreased cytokine production and reduced T cell survival (Nishimura et al., 1999, Immunity 11:141; Nishimura et al., 2001, Science 291:319; Chemitz et al., 2004, J. Immunol. 173:945).
[0003] Viral macrophage inflammatory protein-II (vMIP-II) is a chemokine encoded by human herpesvirus 8 (HHV-8) that interacts with CC and CXC chemokine receptors, including the CCR5 and CXCR4 chemokine receptors. vMIP-II inhibition of HIV-1 entry is mediated through the HIV-1 receptors CCR3, CCR5, and CXCR4 for HIV-1 entry into target cells.
[0004] T cell activation and maintenance of T cell effector functions are controlled by a complex interplay of positive and negative signals. Members of the TNF ligand / TNF receptor superfamily occupy a key position in this signaling ensemble, bridging signals between immune system cells and between immune system cells and cells of other organ systems. In this way, TNF superfamily members contribute to both homeostasis and pathogenesis through their effects on cell survival and death, cell differentiation, and inflammation.
[0005] There is a need for improved therapeutic agents for the treatment of diseases such as cancer. The present invention addresses this need. Summary of the Invention
[0006] As described herein, the present invention relates to fusion proteins with multipoint molecular attachment capability and uses of the fusion proteins.
[0007] One embodiment of the invention includes a fusion protein comprising component A and / or component B. Component A comprises component Y, component Z2, and component Z3. Component B comprises component X', component Z2', and component Z3'.
[0008] Another aspect of the invention includes a fusion protein comprising component A, component B, and component C. Component A comprises component Y, component Z2, and component Z3. Component B comprises component X', component Z2', and component Z3'. Component C comprises component X and component C'. L Component Y comprises at least a portion of PD-1, components Z2 and Z2' comprise the CH2 domain of human Fc, and components Z3 and Z3' comprise the CH3 domain of human Fc. Components X' and X comprise at least a portion of vMIP-II, and component CL' comprises at least one CH1 domain of human IgG1κ.
[0009] Yet another aspect of the invention includes a method of producing a fusion protein comprising administering to a cell a first nucleic acid encoding human PD-1-hFcA, a second nucleic acid encoding vMIPII-CH'-hFcB, and a third nucleic acid encoding vMIPII-CL'.
[0010] Yet another aspect of the invention includes a fusion protein comprising the amino acid sequences of SEQ ID NO:14, SEQ ID NO:49, and SEQ ID NO:57.
[0011] Another aspect of the present invention includes a pharmaceutical composition comprising a pharma- ceutically acceptable carrier and any of the fusion proteins disclosed herein.
[0012] Another aspect of the invention includes a method of treating a proliferative disorder in a patient comprising administering to a patient in need of such treatment a therapeutically effective amount of any of the fusion proteins disclosed herein.
[0013] In various embodiments of the above aspects or any other aspects of the invention detailed herein, component B further comprises component Z1'. In certain embodiments, component A further comprises component Z1.
[0014] In certain embodiments, the fusion protein further comprises a component C, which comprises component X and component C. L ' is included.
[0015] In certain embodiments, the fusion protein further comprises component D, which is a mixture of component Q and component C. L Includes.
[0016] In certain embodiments, component Y comprises a ligand domain, a receptor domain, an scFv domain, or a lipocalin domain. In certain embodiments, component Y comprises at least a portion of PD-1, CD112R, CD113, or MHC-I polypeptide-associated sequence A (MICA).
[0017] In certain embodiments, the fusion protein binds to PD-L1 or PD-L2.
[0018] In certain embodiments, component X' comprises a virus-derived peptide, a ligand-derived peptide, a receptor-derived peptide, or an HTS-selected peptide.
[0019] In certain embodiments, component X' comprises at least a portion of vMIP-II, hi certain embodiments, component X' comprises V1 or V1Δ.
[0020] In certain embodiments, component X comprises a virus-derived peptide, a ligand-derived peptide, a receptor-derived peptide, or an HTS-selected peptide. In certain embodiments, component X comprises V1 or V1Δ.
[0021] In certain embodiments, the fusion protein binds to CXCR4.
[0022] In one particular embodiment, component Y and component Z2 are connected via a hinge. In one particular embodiment, component Z1' and component Z2' are connected via a hinge.
[0023] In certain embodiments, component X′ and component Z′ are connected via a linker. In certain embodiments, component X and component C L In certain embodiments, components Q and C are connected via a linker. L are connected via a linker.
[0024] In certain embodiments, the fusion protein binds to a receptor or ligand on an immune cell, hi certain embodiments, the receptor is an Fc receptor.
[0025] In certain embodiments, component X' comprises at least a portion of PD-1, TIGIT, CD96, CD112R, CD113, CD155, CD111, CD112, MHC-I polypeptide-related sequence A (MICA), NKG2A (CD94), MICB, ULBP1-5, TIM-3, CD226, NECL2, CRTAM, CD80, CTLA-4, KIR2DL1 / 2 / 3, or CD48.
[0026] In certain embodiments, component Y comprises at least a portion of PD-1, TIGIT, CD96, CD112R, CD113, CD155, CD111, CD112, MHC-I polypeptide-related sequence A (MICA), NKG2A (CD94), MICB, ULBP1-5, TIM-3, CD226, NECL2, CRTAM, CD80, CTLA-4, KIR2DL1 / 2 / 3, or CD48.
[0027] In certain embodiments, component X comprises at least a portion of PD-1, TIGIT, CD96, CD112R, CD113, CD155, CD111, CD112, MHC-I polypeptide-related sequence A (MICA), NKG2A (CD94), MICB, ULBP1-5, TIM-3, CD226, NECL2, CRTAM, CD80, CTLA-4, KIR2DL1 / 2 / 3, or CD48.
[0028] In certain embodiments, component Q comprises at least a portion of PD-1, TIGIT, CD96, CD112R, CD113, CD155, CD111, CD112, MHC-I polypeptide-related sequence A (MICA), NKG2A (CD94), MICB, ULBP1-5, TIM-3, CD226, NECL2, CRTAM, CD80, CTLA-4, KIR2DL1 / 2 / 3, or CD48.
[0029] In certain embodiments, component A comprises any one of the amino acid sequences set forth in SEQ ID NO:14 to SEQ ID NO:22.
[0030] In certain embodiments, component B comprises any one of the amino acid sequences of SEQ ID NO: 32 to SEQ ID NO: 35. In certain embodiments, component B comprises any one of the amino acid sequences of SEQ ID NO: 49 to SEQ ID NO:55.
[0031] In a particular embodiment, component A comprises any one of the amino acid sequences set forth in SEQ ID NOs: 14 to 22, and component B comprises any one of the amino acid sequences set forth in SEQ ID NOs: 32 to 35.
[0032] In certain embodiments, component C comprises the amino acid sequence of any one of SEQ ID NO:57 to SEQ ID NO:63.
[0033] In a particular embodiment, component B comprises the amino acid sequence of any one of SEQ ID NOs: 49 to 55, and component C comprises the amino acid sequence of any one of SEQ ID NOs: 57 to 63.
[0034] In certain embodiments, the fusion protein is capable of binding to (i) PD-L1 or PD-L2, (ii) CXCR4, and (iii) an Fc receptor or ligand on an immune cell.
[0035] In one particular embodiment, component A comprises the amino acid sequence of SEQ ID NO:29 and component B comprises the amino acid sequence of SEQ ID NO:30.
[0036] In certain embodiments, component Y comprises the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:2.
[0037] In certain embodiments, component Z2 comprises the amino acid sequence of SEQ ID NO:12 and / or component Z3 comprises the amino acid sequence of SEQ ID NO:13.
[0038] In certain embodiments, component A comprises the amino acid sequence of SEQ ID NO:14 or SEQ ID NO:15.
[0039] In one particular embodiment, component B comprises the amino acid sequence of SEQ ID NO:49.
[0040] In certain embodiments, component X' comprises the amino acid sequence of SEQ ID NO: 37. In certain embodiments, component X comprises the amino acid sequence of SEQ ID NO: 37.
[0041] In certain embodiments, component Z2' comprises SEQ ID NO:12 and / or component Z3' comprises SEQ ID NO:48.
[0042] In certain embodiments, component C L ' comprises the amino acid sequence of SEQ ID NO:64.
[0043] In one particular embodiment, component B comprises the amino acid sequence of SEQ ID NO:53.
[0044] In one particular embodiment, component C comprises the amino acid sequence of SEQ ID NO:61.
[0045] In one particular embodiment, component A comprises the amino acid sequence of SEQ ID NO:14, component B comprises the amino acid sequence of SEQ ID NO:53, and component C comprises the amino acid sequence of SEQ ID NO:61.
[0046] In certain embodiments, the method comprises the first nucleic acid encoding the amino acid sequence of SEQ ID NO: 14, and / or the second nucleic acid encoding the amino acid sequence of SEQ ID NO: 49, and / or the third nucleic acid encoding the amino acid sequence of SEQ ID NO: 57.
[0047] In certain embodiments, the proliferative disorder is cancer. In certain embodiments, the cancer is a solid tumor. In certain embodiments, the cancer is pancreatic cancer, breast cancer, ovarian cancer, bladder cancer, melanoma, glioblastoma, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), multiple myeloma, or colon cancer.
[0048] The following detailed description of the preferred embodiments of the invention will be better understood when read in conjunction with the accompanying drawings, in which presently preferred embodiments are shown for the purpose of illustrating the invention, it being understood, however, that the invention is not limited to the precise arrangements and instrumentalities of the embodiments shown in these drawings. [Brief description of the drawings]
[0049] [Figure 1A] FIG. 1A is a schematic diagram of some embodiments of a fusion protein platform. [Figure 1B] FIG. 1B is a schematic diagram of some embodiments of the fusion protein platform. [Diagram 2] Figure 2 is a schematic diagram of several embodiments of the fusion protein platform, illustrating a fusion protein that targets the interface between natural killer (NK) cells and tumor cells. [Diagram 3] FIG. 3 is a schematic diagram of a fusion protein that binds CXCR4, PD-L1, and FcγRIIIa. [Figure 4] FIG. 4 is a schematic diagram of the interaction of fusion proteins that bind CXCR4, PD-L1, and FcγRIIIa with cancer cells and with NK cells. [Diagram 5] FIG. 5 is a schematic diagram of the possible interactions of fusion proteins that bind CXCR4, PD-L1, and FcγRIIIa with various cell types. [Figure 6] FIG. 6 is a schematic diagram of possible interactions between different fusion proteins and different types of cells. [Figure 7] FIG. 7 is a schematic diagram of possible interactions between different fusion proteins and different types of cells. [Figure 8] FIG. 8 is a schematic diagram of possible interactions between various fusion proteins and tumor-associated macrophages (M1). [Figure 9] FIG. 9 is a Coomassie blue stained (reduced) SDS-PAGE gel of hPD-1-FcA / hFcB (SEQ ID NO:14 and SEQ ID NO:36). [Figure 10] FIG. 10 is a Coomassie blue stained SDS-PAGE gel of hFcA / hFcB (SEQ ID NO:23 and SEQ ID NO:36). [Figure 11] FIG. 11 is a Coomassie blue stained SDS-PAGE gel of hMICA-FcA / hFcB (SEQ ID NO:22 and SEQ ID NO:36). [Figure 12] FIG. 12 is a Coomassie blue stained (reduced) SDS-PAGE gel of hFcA / hTIGIT-FcB (sequence numbers 14 and 36), hFcA / hCD155-FcB (sequence numbers 23 and 32), hFcA / hFcB (sequence numbers 23 and 36), and hMICA-FcA / hTIGIT-FcB (sequence numbers 22 and 33). [Figure 13] FIG. 13 is a Coomassie blue stained SDS-PAGE gel of hCD112R-FcA / hFcB (SEQ ID NO: 16 and SEQ ID NO: 36). [Figure 14] FIG. 14 is a Coomassie blue stained SDS-PAGE gel of HA-PD-1-FcA / hCD113-FcB (SEQ ID NO: 15 and SEQ ID NO: 35). [Figure 15] FIG. 15 is a Coomassie blue stained SDS-PAGE gel of hFcA / hCD113-FcB (SEQ ID NO:23 and SEQ ID NO:33) and PD-1-hFcA / hCD113-FcB (SEQ ID NO:14 and SEQ ID NO:35). [Figure 16] FIG. 16 is a Coomassie blue stained SDS-PAGE gel of hFcA / hCD155-FcB (SEQ ID NO:23 and SEQ ID NO:32). [Figure 17] FIG. 17 is a Coomassie blue stained SDS-PAGE gel of hFcA / TIM-3-hFcB (SEQ ID NO:23 and SEQ ID NO:34) and PD-1-hFcA / TIM-3-hFcB (SEQ ID NO:14 and SEQ ID NO:34). [Figure 18] FIG. 18 shows that hFcA / hTIGIT-FcB (SEQ ID NO: 23 and SEQ ID NO: 33) binds to human CD155-expressing cells. [Figure 19]FIG. 19 shows that hFcA / hTIGIT-FcB (SEQ ID NO: 23 and SEQ ID NO: 33) binds to human CD112-expressing cells. [Figure 20] FIG. 20 shows that hFcA / hCD155-FcB (SEQ ID NO: 23 and SEQ ID NO: 32) binds to human TIGIT-expressing cells. [Figure 21] FIG. 21 shows that hFcA / hTIGIT-FcB (SEQ ID NO: 23 and SEQ ID NO: 33) and hFcA / hCD155-FcB (SEQ ID NO: 23 and SEQ ID NO: 32) bind to CD16 (FcγRIIIa)-expressing cells. [Figure 22] 22 shows the fusion proteins separated on SDS-PAGE and reduced (R) and Coomassie gel stained. As indicated, "A" refers to hFcA / hFcB (SEQ ID NO:23 and SEQ ID NO:36), "B" refers to PD-1-hFcA / FcB (SEQ ID NO:14 and SEQ ID NO:36), "C" refers to hFcA / VpI-CH'-FcB / VpI-CL (SEQ ID NO:23 plus SEQ ID NO:53 and SEQ ID NO:61), and "D" refers to PD-1-hFcA / VpI-CH'-FcB / VpI-CL (SEQ ID NO:14 plus SEQ ID NO:53 and SEQ ID NO:61). [Figure 23A] Figures 23A-D are a series of Western blots. Western blot analysis was performed on Protein A purified fusion proteins purified from conditioned medium of Expi-CHO cells transfected with the expression constructs shown in Figure 22. The bands observed were consistent with the predicted sizes of PD-1-hFcA (SEQ ID NO: 14) and vMIPII-CL' (SEQ ID NO: 57), 125 kDa for the non-reduced (NR) sample and 60 kDa and 20 kDa for the reduced (R) sample, respectively. Anti-PD1 antibody (Figure 23A), anti-IgG kappa light chain antibody (Figure 23B), anti-IgG heavy chain antibody (Figure 23C), and anti-vMIP-II antibody (Figure 23D) were used to probe the Western blot. [Figure 23B]Figures 23A-D are a series of Western blots. Western blot analysis was performed on Protein A purified fusion proteins purified from conditioned medium of Expi-CHO cells transfected with the expression constructs shown in Figure 22. The bands observed were consistent with the predicted sizes of PD-1-hFcA (SEQ ID NO: 14) and vMIPII-CL' (SEQ ID NO: 57), 125 kDa for the non-reduced (NR) sample and 60 kDa and 20 kDa for the reduced (R) sample, respectively. Anti-PD1 antibody (Figure 23A), anti-IgG kappa light chain antibody (Figure 23B), anti-IgG heavy chain antibody (Figure 23C), and anti-vMIP-II antibody (Figure 23D) were used to probe the Western blot. [Figure 23C] Figures 23A-D are a series of Western blots. Western blot analysis was performed on Protein A purified fusion proteins purified from conditioned medium of Expi-CHO cells transfected with the expression constructs shown in Figure 22. The bands observed were consistent with the predicted sizes of PD-1-hFcA (SEQ ID NO: 14) and vMIPII-CL' (SEQ ID NO: 57), 125 kDa for the non-reduced (NR) sample and 60 kDa and 20 kDa for the reduced (R) sample, respectively. Anti-PD1 antibody (Figure 23A), anti-IgG kappa light chain antibody (Figure 23B), anti-IgG heavy chain antibody (Figure 23C), and anti-vMIP-II antibody (Figure 23D) were used to probe the Western blot. [Figure 23D] Figures 23A-D are a series of Western blots. Western blot analysis was performed on Protein A purified fusion proteins purified from conditioned medium of Expi-CHO cells transfected with the expression constructs shown in Figure 22. The bands observed were consistent with the predicted sizes of PD-1-hFcA (SEQ ID NO: 14) and vMIPII-CL' (SEQ ID NO: 57), 125 kDa for the non-reduced (NR) sample and 60 kDa and 20 kDa for the reduced (R) sample, respectively. Anti-PD1 antibody (Figure 23A), anti-IgG kappa light chain antibody (Figure 23B), anti-IgG heavy chain antibody (Figure 23C), and anti-vMIP-II antibody (Figure 23D) were used to probe the Western blot. [Figure 24] Figure 24 shows that fusion proteins bind to B16 melanoma cell lines expressing PD-L1 and CXCR4 or CXCR7 on the cell surface. The fusion proteins tested were (from top to bottom) hFcA / hFcB (SEQ ID NO:23 and SEQ ID NO:36), PD-1-hFcA / FcB (SEQ ID NO:14 and SEQ ID NO:36), hFcA / V1Δmut-CH'-FcB / V1Δmut-CL' (SEQ ID NO:23 plus SEQ ID NO:52 and SEQ ID NO:60), hFcA / V1Δ-CH'-FcB / V1Δ-CL' (SEQ ID NO:23 plus SEQ ID NO:51 and SEQ ID NO:59), PD-1-hFcA / V1Δmut-CH'-FcB / V1Δmut-CL' (SEQ ID NO:14 plus SEQ ID NO:52 and SEQ ID NO:60), and PD-1-hFcA / V1Δ-CH'-FcB / V1Δ-CL' (SEQ ID NO:14 plus SEQ ID NO:51 and SEQ ID NO:59). [Diagram 25] Figure 25 shows a transwell assay evaluating the inhibitory effect of fusion proteins on cell migration of melanoma cells. Representative images of a single transwell migration assay in which migrated B16-F10 cells were treated with 100 ng / mL CXCL12 and fusion proteins are shown. The fusion proteins tested were (from top to bottom) hFcA / hFcB (SEQ ID NO:23 and SEQ ID NO:36), PD-1-hFcA / FcB (SEQ ID NO:14 and SEQ ID NO:36), hFcA / V1Δmut-CH'-FcB / V1Δmut-CL' (SEQ ID NO:23 plus SEQ ID NO:52 and SEQ ID NO:60), hFcA / V1Δ-CH'-FcB / V1Δ-CL' (SEQ ID NO:23 plus SEQ ID NO:51 and SEQ ID NO:59), PD-1-hFcA / V1Δmut-CH'-FcB / V1Δmut-CL' (SEQ ID NO:14 plus SEQ ID NO:52 and SEQ ID NO:60), and PD-1-hFcA / V1Δ-CH'-FcB / V1Δ-CL' (SEQ ID NO:14 plus SEQ ID NO:51 and SEQ ID NO:59). 2% crystal violet was used to stain the assay. [Figure 26A]Figure 26A shows inhibition of tumor growth mediated by fusion protein (FP) PD1-hFcA / v1Δ-CH'-hFcB / v1Δ-CL' (SEQ ID NO: 51 and SEQ ID NO: 59 in addition to SEQ ID NO: 14) in a B16F10 melanoma subcutaneous model. C57BL / 6 mice were treated with (10 μg / mL) FP in 100 μl PBS (mouse R, mouse 2L, and mouse 2R) or PBS only (mouse X or mouse L) on days 13, 14, 15, 16, and 21 after subcutaneous inoculation of 1×105 B16F10 tumor cells. Tumor size over time was measured and plotted for each mouse in Figure 26A. [Figure 26B] Figure 26B shows representative images of one mouse in the PBS only treatment group (top) and one mouse in the PD1-hFcA / v1Δ-CH'-hFcB / v1Δ-CL'(FP) treatment group (bottom). [Figure 27] FIG. 27 shows that NK cell-mediated ADCC is enhanced by the addition of multifunctional fusion proteins. SKOV-3 ovarian cell line [target cells (T)] was seeded at 3000 cells / well in 96-well plates, allowed to adhere, and labeled using Cell Tracker Red CMTPX reagent. SKOV-3 cells were then labeled using green fluorescent caspase-3 reagent. CD16.NK-92 cell line [V158 mutant; effector cells (E)] was added to the wells at a 5:1 effector:target ratio with or without various fusion proteins at a concentration of 25 mg / ml and analyzed by measuring the number of fluorescent double positive (red + green) cells using the Incucyte live cell analysis system. Results shown are from the 20 hour time point. The fusion proteins tested were high affinity (HA)-PD-1-hFcA / FcB (SEQ ID NO:15 and SEQ ID NO:36), hFcA / hCD113-FcB (SEQ ID NO:23 and SEQ ID NO:35), and high affinity (HA)-PD-1-hFcA / hCD113-FcB (SEQ ID NO:15 and SEQ ID NO:35). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0050] definition Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice of testing the present invention, the materials and methods described herein are the preferred materials and methods. The following terms are used in describing and claiming the present invention.
[0051] It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting.
[0052] The articles "a" and "an" are used herein to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. By way of example, "an element" means one element or more than one element.
[0053] As used herein, "about" when referring to a measurable value such as an amount, time, and the like, is meant to encompass variations that are appropriate to the practice of the disclosed methods, such as ±20% or ±10% variation from the stated value, more preferably ±5% variation, even more preferably ±1% variation, and even more preferably ±0.1% variation.
[0054] As used herein, "activation" refers to a state of T cells that has been sufficiently stimulated to induce one or more of cytokine production, detectable effector function, and cell proliferation. The term "activated T cells" specifically refers to T cells that exhibit one or more of these characteristics of activation.
[0055] As used herein, the term "antibody" refers to an immunoglobulin molecule that specifically binds to an antigen. An antibody can be a complete immunoglobulin of natural or recombinant origin or an immunoreactive portion of a complete immunoglobulin. Antibodies are typically tetrameric immunoglobulin molecules and may exist as higher order multimers composed of such tetramers. The antibodies of the present invention may exist in a variety of forms including, for example, polyclonal, monoclonal, Fv, Fab, and F(ab)2, as well as single chain antibodies (scFv) and humanized antibodies (Harlow et al., 1999, Using Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, NY; Harlow et al., 1989, Antibodies: A Laboratory Manual, Cold Spring Harbor, NY; Houston et al., 1988, Proc. Natl. Acad. Sci. USA 85:5879-5883; Bird et al., 1988, Science 242:423-426).
[0056] The term "antibody fragment" refers to a portion of an intact antibody and refers to the antigen-determining variable region of the intact antibody. Examples of antibody fragments include, but are not limited to, Fab, Fab', F(ab')2, and Fv fragments, linear antibodies, scFv antibodies, and multispecific antibodies formed from antibody fragments.
[0057] As used herein, "antibody heavy chain" refers to the larger of the two polypeptide chains present in all antibody molecules in their naturally occurring conformation. Gamma (γ), mu (μ), delta (δ), alpha (α), and epsilon (ε) heavy chains are the five major antibody heavy chain isotypes.
[0058] As used herein, "antibody light chain" refers to the smaller of the two polypeptide chains present in all antibody molecules in their naturally occurring conformation. Kappa (κ) light chain and lambda (λ) light chain are the two major antibody light chain isotypes.
[0059] The term "synthetic antibody" as used herein means an antibody produced using recombinant DNA techniques, such as an antibody expressed by a bacteriophage as described herein, etc. The term should also be taken to mean an antibody produced by synthesis of a DNA molecule encoding an antibody and expressing RNA encoding the antibody protein, or synthesis of an amino acid sequence defining said antibody, said DNA, RNA or amino acid sequence being obtained using nucleic acid or amino acid sequence synthesis techniques available and well known in the art.
[0060] The term "antigen" or "Ag" as used herein is defined as a molecule that induces an immune response or binds to an immune recognition moiety such as a T cell receptor. This immune response may involve either or both the production of antibodies or the activation of specific immunocompetent cells. Those skilled in the art will appreciate that any macromolecule, including virtually any protein or peptide, can serve as an antigen. Furthermore, antigens can be derived from recombinant or genomic DNA. Those skilled in the art will appreciate that any DNA that contains a nucleotide sequence or a partial nucleotide sequence that encodes a protein that induces an immune response therefore encodes an "antigen" as the term is used herein. Furthermore, those skilled in the art will appreciate that an antigen is not necessarily encoded solely by the full-length nucleotide sequence of a gene. It will be readily understood that the present invention includes, but is not limited to, the use of partial nucleotide sequences of more than one gene, and that these nucleotide sequences are arranged in various combinations to induce a desired immune response. It will also be appreciated by those skilled in the art that antigens are not necessarily encoded entirely by "genes". It will be readily understood that antigens can be generated, synthesized, or derived from a biological sample. Such biological samples may include, but are not limited to, a tissue sample, a tumor sample, a cell sample, or a biological fluid.
[0061] The term "anti-tumor effect" as used herein refers to a biological effect that may be manifested by a reduction in tumor volume, a reduction in tumor cell number, a reduction in the number of metastases, an increase in life expectancy, or an improvement in various physiological symptoms associated with cancer conditions. An "anti-tumor effect" may also be manifested primarily by the ability of the peptides, polynucleotides, cells, and antibodies of the present invention in preventing tumor development.
[0062] According to the present invention, the term "autoantigen" refers to any self-antigen that is recognized as foreign by the immune system, including, but not limited to, cell surface receptors, cellular proteins, phosphoproteins, cell surface proteins, cellular lipids, nucleic acids, and glycoproteins.
[0063] The term "autoimmune disease" used herein is defined as a disorder resulting from autoimmune response.Autoimmune disease is the result of inappropriate and excessive response to self-antigen.Examples of autoimmune disease include, but are not limited to, Addison's disease, alopecia areata, ankylosing spondylitis, autoimmune hepatitis, autoimmune parotitis, Crohn's disease, diabetes mellitus (type I), dystrophic epidermolysis bullosa, epididymitis, glomerulonephritis, Graves' disease, Guillain-Barre syndrome, Hashimoto's disease, hemolytic anemia, systemic lupus erythematosus, multiple sclerosis, myasthenia gravis, pemphigus vulgaris, psoriasis, rheumatic fever, rheumatoid arthritis, sarcoidosis, scleroderma, Sjogren's syndrome, spondyloarthropathy, thyroiditis, vasculitis, vitiligo vulgaris, myxedema, pernicious anemia, ulcerative colitis, among others.
[0064] As used herein, the term "autologous" refers to any material that is derived from an individual and is later reintroduced into the same individual.
[0065] "Allogeneic" refers to a graft derived from a different animal of the same species.
[0066] "Xenogeneic" refers to a graft derived from an animal of a different species.
[0067] The term "cancer" as used herein is defined as a disease characterized by rapid and uncontrolled growth and / or accumulation of abnormal cells. Cancer cells can spread locally or to other parts of the body via the bloodstream and lymphatic system. Examples of various cancers include, but are not limited to, breast cancer, prostate cancer, ovarian cancer, cervical cancer, skin cancer, pancreatic cancer, colon cancer, kidney cancer, liver cancer, brain cancer, lymphoma, leukemia, lung cancer, etc. In certain embodiments, the cancer is medullary thyroid cancer.
[0068] The term "cleavage" refers to the cleavage of a covalent bond, e.g., the cleavage of the backbone of a nucleic acid molecule. Cleavage can be initiated by a variety of methods, including, but not limited to, enzymatic or chemical hydrolysis of a phosphodiester bond. Both single-strand and double-strand breaks are possible. Double-strand breaks can result from two separate single-strand cleavage events. DNA cleavage can produce either blunt ends or overhanging ends. In certain embodiments, fusion polypeptides can be used to target cleaved double-stranded DNA.
[0069] As used herein, the term "conservative sequence modification" is intended to refer to an amino acid modification that does not significantly affect or alter the binding properties of an antibody containing that amino acid sequence. Such conservative modifications include amino acid substitutions, additions, and deletions. Modifications can be introduced into the antibodies of the present invention by standard techniques known in the art, such as site-directed mutagenesis and PCR-mediated mutagenesis. A conservative amino acid substitution is one that replaces an amino acid residue with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine), beta-branched side chains (e.g., threonine, valine, isoleucine), and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, one or more amino acid residues in the CDR regions of an antibody can be substituted with other amino acid residues from the same side chain family, and the modified antibodies can be tested for their ability to bind to antigen using the functional assays described herein.
[0070] A "disease" is an animal's condition of health in which homeostasis is not maintained and which, if not corrected, will result in the animal's health continuing to deteriorate. A "disorder" in an animal is an animal's condition of health in which homeostasis is maintained but which is less favorable than it would be if the disorder did not exist. A disorder, if left untreated, does not necessarily result in the animal's health becoming worse.
[0071] "Effective amount" or "therapeutically effective amount" are used interchangeably herein and refer to an amount of a compound, formulation, substance, or composition as described herein effective to achieve a particular biological outcome or to realize a therapeutic or prophylactic benefit. Such outcome may include, but is not limited to, anti-tumor activity as determined by any means suitable in the art.
[0072] "Encoding" refers to the inherent property of a particular nucleotide sequence in a polynucleotide (such as a gene, cDNA, or mRNA) to serve as a template for the synthesis in biological processes of other polymers and macromolecules that have either a defined nucleotide sequence (i.e., rRNA, tRNA, and mRNA) or a defined amino acid sequence and that have biological properties that result from that sequence. Thus, a gene encodes a protein if transcription into its corresponding mRNA and translation of the mRNA results in the protein in a cell or other biological system. Both the coding strand, whose nucleotide sequence is identical to the mRNA sequence and which is typically presented in a sequence listing, and the non-coding strand, which is used as a template for transcription of a gene or cDNA, may be referred to as encoding the protein or other product of the gene or cDNA.
[0073] As used herein, "endogenous" refers to any substance that originates or is produced inside an organism, cell, tissue, or system.
[0074] As used herein, the term "exogenous" refers to any substance that is introduced from or produced outside an organism, cell, tissue, or system.
[0075] The term "expand" as used herein refers to an increase in number, such as an increase in the number of T cells. In one embodiment, ex vivo expanded T cells are increased in number compared to the number originally present when cultured. In another embodiment, ex vivo expanded T cells are increased in number compared to other types of cells when cultured. As used herein, the term "ex vivo" refers to cells that have been removed from a living organism (e.g., a human) and propagated outside of the living organism (e.g., in a culture dish, test tube, or bioreactor).
[0076] The term "expression" as used herein is defined as the transcription and / or translation of a particular nucleotide sequence directed by a control element, such as a promoter.
[0077] "Expression vector" refers to a vector that contains a recombinant polynucleotide that includes an expression control sequence operably linked to the nucleotide sequence to be expressed. An expression vector contains sufficient cis-acting elements for expression, and other elements for expression may be provided in a host cell or in an in vitro expression system. Expression vectors include all vectors known in the art that incorporate the recombinant polynucleotide, such as cosmids, plasmids (e.g., naked or contained in liposomes), and viruses (e.g., Sendai virus, lentivirus, retrovirus, adenovirus, and adeno-associated virus).
[0078] "Homologous" as used herein refers to the subunit sequence identity between two polymers, e.g., between two nucleic acid molecules, such as two DNA molecules or two RNA molecules, or between two polypeptide molecules. If both subunit positions of the two molecules are occupied by the same monomeric subunit, e.g., if a position in each of the two DNA molecules is occupied by adenine, the molecules are homologous at that position. The homology between two sequences is a linear function of the number of matching or homologous positions. For example, two sequences are 50% homologous if half of the positions in the two sequences are homologous (e.g., 5 positions in a polymer 10 subunits in length), and the two sequences are 90% homologous if 90% of the positions (e.g., 9 out of 10) are matched or homologous.
[0079] "Humanized" forms of non-human (e.g., murine) antibodies are chimeric immunoglobulins, immunoglobulin chains, or fragments thereof (e.g., Fv, Fab, Fab', F(ab')2, or other antigen-binding subsequences of antibodies) that contain minimal sequence derived from non-human immunoglobulin. For the most part, humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a complementarity determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat, or rabbit having the desired specificity, affinity, and capacity. In some instances, Fv framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, humanized antibodies may comprise residues that are found neither in the recipient antibody nor in the imported CDR or framework sequences. These modifications are made to further refine and optimize antibody performance. Generally, a humanized antibody will comprise substantially all of at least one, and typically two, variable domains in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin sequence. Optimally, the humanized antibody will also comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. For further details, see Jones et al., Nature 321:522-525 (1986); Reichmann et al., Nature 332:323-329 (1988); Presta, Curr. Op. Struct. Biol. 2:593-596 (1992).
[0080] "Fully human" refers to an immunoglobulin, such as an antibody, whose entire molecule is of human origin or whose entire molecule consists of the same amino acid sequence as a human version of said antibody.
[0081] "Identity" as used herein refers to the subunit sequence identity between two polymers, particularly between two amino acid molecules, e.g., between two polypeptide molecules. If two amino acid sequences have the same residue at the same position, e.g., if a position in each of the two polypeptide molecules is occupied by arginine, then the molecules are identical at that position. Identity, or the degree to which two aligned amino acid sequences have the same residue at the same position, is often expressed as a percentage. Identity between two amino acid sequences is a direct function of the number of matching or identical positions. For example, if half of the positions in the two sequences (e.g., 5 positions in a polymer 10 amino acids in length) are identical, the two sequences are 50% identical, and if 90% of the positions (e.g., 9 out of 10) are matched or identical, the two amino acid sequences are 90% identical.
[0082] As used herein, the term "immunoglobulin" or "Ig" is defined as a class of proteins that function as antibodies. Antibodies expressed by B cells are sometimes referred to as BCRs (B cell receptors) or antigen receptors. The five members of this class of proteins are IgG, IgM, IgD, IgA, and IgE. IgG is the most common circulating antibody. IgM is the major immunoglobulin produced in the early immune response of most subjects. It is the most efficient immunoglobulin in agglutination, complement fixation, and other antibody responses, and is important in defense against bacteria and viruses. IgD is an immunoglobulin with no known antibody function, but may act as an antigen receptor. IgA is the major antibody present in saliva, tears, breast milk, gastrointestinal secretions, and viscous secretions of the respiratory and genital tracts. IgE is an immunoglobulin that mediates immediate hypersensitivity by triggering the release of mediators from mast cells and basophils upon exposure to allergens.
[0083] The term "immune response" as used herein is defined as a cellular response to an antigen that occurs when lymphocytes recognize an antigen molecule as foreign and induce the formation of antibodies and / or activate lymphocytes to eliminate the antigen.
[0084] The term "lipocalin" as used herein is defined as a class of proteins that function in their natural setting to transport hydrophobic small molecules such as steroids, bilins, retinoids, and lipids. The proteins share limited regions of sequence flexibility and a common tertiary structure that includes an eight-stranded antiparallel β-barrel with a repeat +1 topology surrounding an internal ligand binding site. Lipocalins are found in gram-negative bacteria, vertebrate cells, invertebrate cells, and plants and have been linked to numerous biological processes, among them immune response, pheromone transport, prostaglandin biosynthesis, retinoid binding, and cancer cell interactions. Lipocalins can be modified in many of the same ways described for modifying antibodies, for example to bind cell surface molecules, to alter or enhance their binding properties, thus disrupting, enhancing, or otherwise modifying their functional properties.
[0085] As used herein, "instructional material" includes publications, records, diagrams, or any other means of expression that can be used to communicate the utility of the compositions and methods of the invention. The instructional material of the kits of the invention can be, for example, affixed to a container containing the nucleic acids, peptides, and / or compositions of the invention or shipped together with a container containing the nucleic acids, peptides, and / or compositions. Alternatively, the instructional material can be shipped separately from the container with the recipient using the instructional material cooperatively with the compound.
[0086] "Isolated" means altered or removed from the natural state. For example, a nucleic acid or peptide naturally occurring in a living animal is not "isolated," but the same nucleic acid or peptide partially or completely separated from the materials with which it coexists in its natural state is "isolated." An isolated nucleic acid or protein may exist in a substantially purified form, or it may exist in a non-natural environment, such as a host cell.
[0087] As used herein, "lentivirus" refers to a genus of the Retroviridae family.Lentiviruses are unique among retroviruses in that they can infect non-dividing cells, and lentiviruses are one of the most efficient gene delivery vector methods, as they can deliver a ton of genetic information into the DNA of host cells.HIV, SIV, and FIV are all examples of lentiviruses.Vectors derived from lentiviruses provide a means to achieve high levels of gene transfer in vivo.
[0088] As used herein, the term "modified" refers to a change in the state or structure of a molecule or cell of the invention. Molecules may be modified in many ways, including chemistry, structure, and function. Cells may be modified through the introduction of a nucleic acid.
[0089] As used herein, the term "modulating" means to detectably increase or decrease the level of a response in a subject compared to the level of the response in said subject in the absence of a treatment or compound and / or the level of the response in an otherwise identical untreated subject. The term encompasses perturbing and / or affecting the original signal or response to enact a beneficial therapeutic response in a subject, preferably a human.
[0090] The following commonly occurring nucleobase abbreviations are used within the present invention: "A" refers to adenosine, "C" refers to cytosine, "G" refers to guanosine, "T" refers to thymidine, and "U" refers to uridine.
[0091] Unless otherwise specified, a "nucleotide sequence encoding an amino acid sequence" includes all nucleotide sequences that are degenerate versions of each other and that encode the same amino acid sequence. A nucleotide sequence encoding a protein or RNA may include introns only if the nucleotide sequence encoding the protein is of the type that contains an intron.
[0092] The term "operably linked" refers to a functional linkage between a heterologous nucleic acid sequence and a regulatory sequence that causes expression of the heterologous nucleic acid sequence. For example, a first nucleic acid sequence is operably linked to a second nucleic acid sequence when the first nucleic acid sequence is placed in a functional relationship with the second nucleic acid sequence. For example, a promoter is operably linked to a coding sequence when the promoter affects the transcription or expression of the coding sequence. Operatively linked DNA sequences are generally contiguous and, where necessary to link two protein coding regions, in the same reading frame.
[0093] The term "overexpressed" tumor antigen, or "overexpression" of a tumor antigen, is intended to indicate that the expression level of the tumor antigen in cells derived from a disease area, such as a solid tumor, in a particular tissue or organ of a patient is abnormal compared to the expression level in normal cells derived from that tissue or organ. Patients with solid tumors or hematological malignancies characterized by overexpression of the tumor antigen can be determined by standard assays known in the art.
[0094] Examples of "parenteral" administration of the immunogenic compositions include subcutaneous (sc) injection, intravenous (iv), intramuscular (im) or intrasternal injection, or infusion techniques.
[0095] The term "polynucleotide" as used herein is defined as a chain of nucleotides. Furthermore, a nucleic acid is a polymer of nucleotides. Thus, as used herein, nucleic acid and polynucleotide are interchangeable. Those skilled in the art have the general knowledge that a nucleic acid is a polynucleotide and can be hydrolyzed into monomeric "nucleotides". The monomeric nucleotides can be hydrolyzed into nucleosides. As used herein, polynucleotide includes, but is not limited to, any nucleic acid sequence obtained by any means available in the art, including recombinant techniques, i.e., cloning of nucleic acid sequences from recombinant libraries or cell genomes using conventional cloning techniques and PCR™, etc., and synthetic techniques.
[0096] As used herein, the terms "peptide", "polypeptide" and "protein" are used interchangeably and refer to compounds composed of amino acid residues covalently linked by peptide bonds. A protein or peptide must contain at least two amino acids, and there is no limit to the maximum number of amino acids that may make up a protein or peptide sequence. A polypeptide includes any peptide or protein that contains two or more amino acids linked by peptide bonds. As used herein, the term refers to both short and long chains, where short chains are commonly referred to in the art as peptides, oligopeptides, oligomers, etc., and long chains are commonly referred to in the art as proteins, of which there are many varieties. "Polypeptides" include, among others, for example, biologically active fragments, substantially homologous polypeptides, oligopeptides, homodimers, heterodimers, polypeptide variants, modified polypeptides, derivatives, analogs, fusion proteins. Such polypeptides include natural peptides, recombinant peptides, synthetic peptides, or combinations thereof.
[0097] As used herein, the terms "fusion protein" and "chimeric protein" are used interchangeably and refer to a compound composed of two or more polypeptides. In some embodiments, the two or more polypeptides are covalently linked. In other embodiments, the two or more polypeptides are covalently linked by a peptide bond, a linker, or a disulfide bond. Fusion proteins can be made by a number of methods well known to those of skill in the art, most commonly by introducing into a cell a vector that contains a nucleic acid sequence that encodes or specifies the fusion protein amino acid sequence. Additional amino acids or polypeptides can be incorporated into the fusion protein to elicit other functional properties, such as stability, half-life, multimerization, and ease of purification. One example of such an element is a polypeptide linker.
[0098] The term "promoter" as used herein is defined as a DNA sequence required to initiate the specific transcription of a polynucleotide sequence and recognized by or introduced into the synthetic machinery of a cell.
[0099] As used herein, the term "promoter / regulatory sequence" refers to a nucleic acid sequence required for expression of a gene product operably linked to the promoter / regulatory sequence. In some instances, this sequence may be a core promoter sequence, while in other instances, this sequence may include an enhancer sequence and other regulatory elements required for expression of the gene product. The promoter / regulatory sequence may, for example, be one that confers expression of the gene product in a tissue-specific manner.
[0100] A "constitutive" promoter is a nucleotide sequence that, when operably linked to a polynucleotide encoding or specifying a gene product, causes the production of that gene product in a cell under most or all physiological conditions of the cell.
[0101] An "inducible" promoter is a nucleotide sequence which, when operably linked to a polynucleotide encoding or specifying a gene product, causes said gene product to be produced in a cell substantially only when an inducer corresponding to the promoter is present in said cell.
[0102] A "tissue-specific" promoter is a nucleotide sequence that, when operably linked to a polynucleotide encoding or specifying a gene product, causes the gene product to be produced in a cell substantially only if the cell is a cell of a tissue type corresponding to the promoter.
[0103] "Signal transduction pathway" refers to the biochemical relationships between various signaling molecules that play a role in transmitting a signal from one part of a cell to another part of the cell. The term "cell surface receptor" includes molecules and complexes of molecules that are capable of receiving and transmitting a signal across the plasma membrane of a cell.
[0104] The term "specifically binds" as used herein with respect to an antibody means an antibody that recognizes a particular antigen in a sample but does not substantially recognize or bind other molecules. For example, an antibody that specifically binds to an antigen of one species may also bind that antigen of one or more species. However, such cross-species cross-reactivity in itself does not change the classification of the antibody as specific. In another example, an antibody that specifically binds to an antigen may also bind to different allelic forms of the antigen. However, such cross-reactivity in itself does not change the classification of the antibody as specific. In some examples, the terms "specific binding" or "specifically binds" can be used when referring to the interaction of an antibody, protein, or peptide with a second chemical species to mean that the interaction is dependent on the presence of a particular structure (e.g., an antigenic determinant or epitope) on the chemical species. For example, an antibody recognizes and binds to a particular protein structure rather than the entire protein. If an antibody is specific for epitope "A", the presence of a molecule containing epitope A (or free unlabeled A) reduces the amount of labeled A that binds to the antibody in a reaction involving labeled "A" and the antibody.
[0105] The term "subject" is intended to include organisms (e.g., mammals) in which an immune response can be elicited. As used herein, a "subject" or "patient" may be a human or a non-human mammal. Examples of non-human mammals include farm animals and pets, such as ovine, bovine, porcine, canine, feline, and murine mammals. Preferably, the subject is a human.
[0106] As used herein, "substantially purified" cells are cells that are essentially free of other types of cells. Substantially purified cells also refer to cells that are separated from other types of cells with which they are normally associated in their native state. In some instances, a population of substantially purified cells refers to a homogenous cell population. In other instances, the term simply refers to cells that are separated from the cells with which they are normally associated in their native state. In some embodiments, the cells are cultured in vitro. In other embodiments, the cells are not cultured in vitro.
[0107] "Target site" or "target sequence" refers to a genomic nucleic acid sequence that defines a portion of a nucleic acid to which a binding molecule can specifically bind under conditions sufficient for binding to occur.
[0108] As used herein, the term "therapeutic" refers to treatment and / or prophylaxis. A therapeutic effect is achieved by suppression, amelioration, or eradication of a disease state.
[0109] As used herein, the terms "transfected" or "transformed" or "transduced" refer to a process for transferring or introducing exogenous nucleic acid into a host cell. A "transfected" or "transformed" or "transduced" cell is one that has been transfected, transformed or transduced with exogenous nucleic acid. Such cells include the initial subject cell and its progeny.
[0110] The term "transgene" refers to genetic material that has been or is to be artificially inserted into the genome of an animal, particularly a mammal, and more particularly a living mammalian cell.
[0111] As used herein, "treating" a disease means reducing the frequency or severity of at least one sign or symptom of the disease or disorder experienced by a subject.
[0112] As used herein, the terms "under transcriptional control" or "operably linked" mean that a promoter is in the correct location and orientation relative to a polynucleotide to control initiation of transcription by RNA polymerase and expression of the polynucleotide.
[0113] A "vector" is a composition that contains an isolated nucleic acid and can be used to deliver the isolated nucleic acid inside a cell. Numerous vectors are known in the art, including, but not limited to, linear polynucleotides, polynucleotides associated with ionic or amphiphilic compounds, plasmids, and viruses. Thus, the term "vector" includes autonomously replicating plasmids or viruses. The term should also be construed to include non-plasmid and non-viral compounds that facilitate the transfer of nucleic acid into cells, such as polylysine compounds, liposomes, and the like. One example of a plasmid vector is an episomal vector, whose autonomous replication is driven or enhanced by regulatory elements derived from viruses, such as Epstein-Barr virus and BK virus. Examples of viral vectors include, but are not limited to, Sendai virus vectors, adenovirus vectors, adeno-associated virus vectors, retrovirus vectors, lentivirus vectors, and the like.
[0114] range Throughout this disclosure, various aspects of the invention may be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity, and the description should not be construed as inflexibly limiting the scope of the invention. Thus, the description of a range should be considered to specifically disclose all possible subranges as well as individual numerical values within that range. For example, the description of a range such as 1-6 should be considered to specifically disclose subranges such as 1-3, 1-4, 1-5, 2-4, 2-6, 3-6, etc., as well as individual numbers within that range (e.g., 1, 2, 2.7, 3, 4, 5, 5.3, and 6). This applies regardless of the size of the range.
[0115] Where any amino acid sequence is specifically referenced by a GENBANK® Accession Number, that sequence is incorporated herein by reference in part and / or in whole. Information associated with the Accession Number, such as identification of signal peptides, extracellular domains, transmembrane domains, promoter sequences, and translation start sites, is also incorporated herein by reference in part and / or in whole.
[0116] As contemplated herein with respect to the compositions and methods of the present disclosure, in one aspect, an embodiment of the invention comprises the components and / or steps disclosed herein. In another aspect, an embodiment of the invention consists essentially of the components and / or steps disclosed herein. In yet another aspect, an embodiment of the invention consists of the components and / or steps disclosed herein.
[0117] explanation Fusion proteins are provided. In some exemplary embodiments, the first component of the fusion protein (through binding of a vMIPII peptide or a V1 peptide or a derivative thereof in the fusion protein) acts to block a chemokine receptor (e.g., CXCR4 and / or CXCR7) which immobilizes tumor cells and impairs their migration, invasiveness, metastasis, and other tumorigenic properties. The second component of the fusion protein (through binding of PD1 or a derivative thereof in the fusion protein) acts to block a checkpoint inhibitor (e.g., PD-L1 and / or PD-L2) on the tumor cells which impairs the inhibition of tumor-directed immune effector cells, such as NK cells. The third component of the fusion protein (through binding of an Fc γ or a derivative thereof) to an activating receptor on the same immune effector cell, e.g., Fc γ It stimulates the RIIIa receptor, thereby causing activation of NK cells and promoting ADCC and ADCP.
[0118] In some exemplary embodiments, one component of the fusion protein blocks a checkpoint inhibitor on a tumor or other cell, and the other two components each stimulate a distinct activating receptor on an immune effector cell. In some embodiments, the fusion protein forms a molecular bridge between the immune effector cell and the target tumor cell when a checkpoint inhibitor is present on the tumor cell. Furthermore, the three interactions of the fusion protein, the combination of blocking a checkpoint inhibitor pathway and stimulating an activating receptor, act to functionally reinforce each other, and all three interactions cooperate to cause activation of said immune effector cells, e.g., NK cells. In a preferred embodiment, the checkpoint inhibitors blocked by the fusion protein consist of PD-L1, PD-L2, CD113, CD112, CD155, or CD111, and the two activating receptors co-stimulated by the fusion protein are 4-1BB and Fc on NK cells. γ The RIIIa receptor.
[0119] Fusion proteins A fusion protein comprising component A and / or component B, component A includes component Y, component Z2, and component Z3; The above fusion protein is provided, wherein component B comprises component X', component Z2', and component Z3'. In some embodiments, component B further comprises component Z1'. Thus, in some embodiments, component B comprises component X', component Z1', component Z2', and component Z3'.
[0120] In some embodiments, component A further comprises component Z1. Thus, in some embodiments, component A comprises component Y, component Z1, component Z2, and component Z3.
[0121] In some embodiments, the fusion protein further comprises a component C, which comprises component X and component C. L In other embodiments, component C L In some embodiments, the fusion protein further comprises a component D, which comprises a component Q and a component C. L In other embodiments, component C L comprises at least a portion of an immunoglobulin light chain.
[0122] In some embodiments, component A further comprises a leader sequence. In other embodiments, the leader sequence is a human albumin leader sequence.
[0123] In some embodiments, component B further comprises a leader sequence. In other embodiments, the leader sequence is a human albumin leader sequence.
[0124] In some embodiments, component Y comprises a ligand domain, a receptor domain, an scFv domain, or a lipocalin domain. In other embodiments, component Y comprises at least a portion of PD-1, TIGIT, CD96, CD112R, CD113, CD155, CD111, CD112, MHC-I polypeptide-related sequence A (MICA), NKG2A (CD94), MICB, ULBP1-5, TIM-3, CD226, NECL2, CRTAM, CD80, CTLA-4, KIR2DL1 / 2 / 3, or CD48. In yet other embodiments, the fusion protein binds to PD-L1 or PD-L2.
[0125] In some embodiments, the component Z1 comprises an immunoglobulin domain, a TNF superfamily member, a TNF-L superfamily member, transferrin, a transferrin receptor, human serum albumin, or a lipocalin. In some embodiments, the immunoglobulin domain is a CH1 domain. In some embodiments, the immunoglobulin is an IgG. In still other embodiments, the immunoglobulin is IgE.
[0126] In some embodiments, the component Z2 comprises an immunoglobulin domain, a TNF superfamily member, a TNF-L superfamily member, transferrin, a transferrin receptor, human serum albumin, or a lipocalin. In some embodiments, the immunoglobulin domain is a CH2 domain. In some embodiments, the immunoglobulin is an IgG. In yet other embodiments, the immunoglobulin is IgE.
[0127] In some embodiments, the component Z3 comprises an immunoglobulin domain, a TNF superfamily member, a TNF-L superfamily member, transferrin, a transferrin receptor, human serum albumin, or a lipocalin. In some embodiments, the immunoglobulin domain is a CH3 domain. In some embodiments, the immunoglobulin is an IgG. In yet other embodiments, the immunoglobulin is IgE.
[0128] In some embodiments, the component Z1' comprises a domain of an immunoglobulin, a TNF superfamily member, a TNF-L superfamily member, transferrin, a transferrin receptor, human serum albumin, or a lipocalin. In some embodiments, the immunoglobulin domain is a CH1 domain. In some embodiments, the immunoglobulin is an IgG. In yet other embodiments, the immunoglobulin is IgE.
[0129] In some embodiments, the component Z2' comprises a domain of an immunoglobulin, a TNF superfamily member, a TNF-L superfamily member, transferrin, a transferrin receptor, human serum albumin, or a lipocalin. In some embodiments, the immunoglobulin domain is a CH2 domain. In some embodiments, the immunoglobulin is an IgG. In yet other embodiments, the immunoglobulin is IgE.
[0130] In some embodiments, the component Z3' comprises a domain of an immunoglobulin, a TNF superfamily member, a TNF-L superfamily member, transferrin, a transferrin receptor, human serum albumin, or a lipocalin. In some embodiments, the immunoglobulin domain is a CH3 domain. In some embodiments, the immunoglobulin is an IgG. In yet other embodiments, the immunoglobulin is IgE.
[0131] In some embodiments, component X' comprises a virus-derived peptide, a ligand-derived, a receptor-derived peptide, or a high-throughput screen (HTS) selected peptide. In some embodiments, component X' comprises a peptide sequence that binds to a chemokine receptor, a cytokine receptor, a counter-receptor of a functional ligand, an integrin, a ligand, or a portion of a membrane signaling complex. In some embodiments, component X' comprises at least a portion of PD-1, TIGIT, CD96, CD112R, CD113, CD155, CD111, CD112, MHC-I polypeptide-related sequence A (MICA), NKG2A (CD94), MICB, ULBP1-5, TIM-3, CD226, NECL2, CRTAM, CD80, CTLA-4, KIR2DL1 / 2 / 3, or CD48. In other embodiments, component X' comprises at least a portion of vMIP-II. In other embodiments, component X' comprises a V1 polypeptide or a V1Δ polypeptide. In still other embodiments, the fusion protein binds to CXCR4.
[0132] In some embodiments, component Q comprises at least a portion of PD-1, TIGIT, CD96, CD112R, CD113, CD155, CD111, CD112, MHC-I polypeptide-related sequence A (MICA), NKG2A (CD94), MICB, ULBP1-5, TIM-3, CD226, NECL2, CRTAM, CD80, CTLA-4, KIR2DL1 / 2 / 3, or CD48.
[0133] In some embodiments, component X comprises a virus-derived peptide, a ligand-derived peptide, a receptor-derived peptide, or an HTS-selected peptide. In other embodiments, component X comprises a V1 polypeptide or a V1Δ polypeptide. In other embodiments, the fusion protein binds to CXCR4.
[0134] In some embodiments, component Y and component Z2 are connected via a hinge (e.g., an IgG hinge). In some embodiments, component Z1' and component Z2' are connected via a hinge (e.g., an IgG hinge). In some embodiments, component X' and component Z1' are connected via a linker. In some embodiments, component X and component C L are connected via a linker.
[0135] In some embodiments, the fusion protein comprises component A and Fc. In other embodiments, the fusion protein comprises component A and human FcB (hFcB).
[0136] In some embodiments, the fusion protein comprises component B and Fc. In other embodiments, the fusion protein comprises component B and human FcA (hFcA).
[0137] In some embodiments, component A is covalently bonded to component B. In some embodiments, the covalent bond is via a disulfide bond or a linker.
[0138] In some embodiments, component A is not covalently linked to component B. In some embodiments, component A and component B are held together via knob-into-hole interactions. In some embodiments, component A and component B comprise knob-into-hole mutations and a covalent bond via a disulfide bond. In some embodiments, component A comprises the mutation Y349C and the mutation T366W, and component B comprises the mutation D356C, the mutation T366S, the mutation L368A, and the mutation Y407V ("knobs-into-hole" mutations). The positions of the mutations and changes within these component chains are defined by the Kabat numbering system (Johnson, G and Wu, TT, (2001) Nucleic Acids Res. 28(1):214-18).
[0139] In some embodiments, the fusion protein comprises component A and an immunoglobulin domain. In some embodiments, the immunoglobulin domain is an Fc domain.
[0140] In some embodiments, the fusion protein comprises component B and an immunoglobulin domain. In some embodiments, the immunoglobulin domain is an Fc domain.
[0141] In some embodiments, component B is covalently bonded to component C. In some embodiments, the covalent bond is via a disulfide bond.
[0142] In some embodiments, component B is not covalently bonded to component C.
[0143] In some embodiments, component A is covalently bonded to component D. In some embodiments, the covalent bond is via a disulfide bond.
[0144] In some embodiments, components A and D are not covalently bonded.
[0145] In some embodiments, the fusion protein binds to a receptor or ligand on an immune cell.
[0146] In some embodiments, the receptor is an Fc receptor.
[0147] Also provided is a pharmaceutical composition comprising a pharma- ceutically acceptable carrier and a fusion protein of any one of the above-mentioned embodiments.
[0148] Also provided is a method of treating a proliferative disorder in a patient, comprising administering to a patient in need of such treatment a therapeutically effective amount of the fusion protein of any one of the above-mentioned embodiments. In some embodiments, the proliferative disorder is cancer. In other embodiments, the cancer is a solid tumor. In still other embodiments, the cancer is pancreatic cancer, breast cancer, ovarian cancer, bladder cancer, melanoma, glioblastoma, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), multiple myeloma, colon cancer, lung cancer, liver cancer, or any solid or liquid tumor type.
[0149] The present invention provides novel fusion proteins useful for treating proliferative disorders such as cancer. On cells expressing a component Y receptor or ligand and a component X' receptor or ligand, the fusion proteins of the present invention can interfere with one or both receptors or ligands. Thus, on cells co-expressing a component Y receptor or ligand and a component X' receptor or ligand, the fusion proteins of the present invention can cause cell death, immobilization, and clearance of tumor cells. Furthermore, on cells expressing a component Z3 or component Z3' receptor or ligand, such as a natural killer (NK) cell, the fusion proteins of the present invention can stimulate the receptor or ligand, causing activation of the cell. Thus, the fusion proteins of the present invention may mediate their activity by spanning two adjacent cells. Furthermore, the fusion proteins of the present invention may bind to three or more different molecules on a cell. In some embodiments, the fusion proteins may act to treat a disease such as cancer by causing inhibition or reduction of a certain cell, or by causing activation or increase of a certain cell.
[0150] Component A The component A includes a component Y, a component Z2, and a component Z3.
[0151] Component Y In some embodiments, component Y comprises a ligand domain, a receptor domain, an scFv domain, or a lipocalin domain. In other embodiments, component Y comprises at least a portion of PD-1, TIGIT, CD96, CD112R, CD113, CD155, CD111, CD112, MHC-I polypeptide-related sequence A (MICA), NKG2A (CD94), MICB, ULBP1-5, TIM-3, CD226, NECL2, CRTAM, CD80, CTLA-4, KIR2DL1 / 2 / 3, or CD48.
[0152] Exemplary sequences of component Y include or consist of the following sequences: GWFLDSPDRPWNPPTFSPALLVVTEGDNATFTCSFSNTSESFVLNWYRMSPSNQTDKLAAFPEDRSQPGQDCRFRVTQLPNGRDFHMSVVRARRNDSGTYLCGAISLAPKAQIKESLRAELRVTERRAEVPTAHPSPSPRPAGQ (SEQ ID NO:1) Human PD-1 extracellular domain, GENBANK® Accession No. NM_005018.3
[0153] Exemplary sequences of component Y include or consist of the following sequences: GWFLDSPDRPWNPPTFSPALLVVTEGDNATFTCSFSNTSESFHVVWHRESPSGQTDTLAAFPEDRSQPGQDCRFRVTQLPNGRDFHMSVVRARRNDSGTYVCGVISLAPKIQIKESLRAELRVTERRAEVPTAHPSPSPRPAGQ (SEQ ID NO:2) High affinity human PD-1 extracellular domain
[0154] Exemplary sequences of component Y include or consist of the following sequences: MMTGTIETTGNISAEKGGSIILQCHLSSTTAQVTQVNWEQQDQLLAICNADLGWHISPSFKDRVAPGPGLGLTLQSLTVNDTGEYFCIYHTYPDGTYTGRIFLEVLESSVAEHGARFQIP (SEQ ID NO:3) Human TIGIT extracellular domain, GENBANK® accession number NM_173799.4
[0155] Exemplary sequences of component Y include or consist of the following sequences: VWEKTVNTEENVYATLGSDVNLTCQTQTVGFFVQMQWSKVTNKIDLIAVYHPQYGFYCAYGRPCESLVTFTETPENGSKWTLHLRNMSCSVSGRYECMLVLYPEGIQTKIYNLLIQTHVTADEW NSNHTIEIEINQTLEIPCFQNSSSKISSEFTYAWSVENSSTDSWVLLSKGIKEDNGTQETLISQNHLISNSTLLKDRVKLGTDYRLHLSPVQIFDDGRKFSCHIRVGPNKILRSSTTVKVFAKPE IPVIVENNSTDVLVERRFTCLLKNVFPKANITWFIDGSFLHDEKEGIYITNEERKGKDGFLELKSVLTRVHSNKPAQSDNLTIWCMALSPVPGNKVWNISSEKITFLLGSEISSTDDPPLSVTES TLDTQPSPASSVSPARYPATSSVTLVDVSALRPNTTPQPSNSSMTTRGFNYPWTSSGTDTKKSVSRIPSETYSSSPSGAGSTLHDNVFTSTARAFSEVPTTANGSTKTNHVHITGIVVNKPKDGM (SEQ ID NO: 4) Human CD96 extracellular domain, GENBANK® accession number NM_198196.2
[0156] Exemplary sequences of component Y include or consist of the following sequences: MGHRTLVLPWVLLTLCVTAGTPEVWVQVRMEATELSSFTIRCGFLGSGSISLVTVSWGGPNGAGGTTLAVLHPERGIRQWAPARQARWETQSSISLILEGSGASSPCANTTFCCKFASFPEGSWEACGSLPPSSDPGLSAPPTPAPILRAD (SEQ ID NO:5) Human CD112R extracellular domain, GENBANK® accession number NM_024070.3
[0157] Exemplary sequences of component Y include or consist of the following sequences: EEVLWHTSVPFAENMSLECVYPSMGILTQVEWFKIGTQQDSIAIFSPTHGMVIRKPYAERVYFLNSTMASNNMTLFFRNASEDDVGYYSCSLYTYPQGTWQKVIQVVQSDSFEAAVPS NSHIVSEPGKNVTLTCQPQMTWPVQAVRWEKIQPRQIDLLTYCNLVHGRNFTSKFPRQIVSNCSHGRWSVIVIPDVTVSDSGLYRCYLQASAGENETFVMRLTVAEGKTDNQYTLFVA (SEQ ID NO:6) Human CD226 extracellular domain, GENBANK® accession number NM_006566.3
[0158] Exemplary sequences of component Y include or consist of the following sequences: QNLFTKDVTVIEGEVATIS HKEDDGVPVICQVEHPAVTGNLQTQRYLEVQYKPQVHIQMTYPLQGLTREGDALELTCEAIGKPQPVMVTWVRVDDEMPQHAVLSGPNLFINNLNKTDNGTYRCEASNIVGKAHSDYMLYVYDPPTTIPPPTTTTTTTTTTTTTILTIITDSRAGEEGSIRAVDH (SEQ ID NO: 7) Human NECL2 extracellular domain, GENBANK® Accession No. NM_014333.3
[0159] Exemplary sequences of component Y include or consist of the following sequences: PIIVEPHVTAVWGKNVSLKCLIEVNETITQISWEKIHGKSSQTVAVHHPQYGFSVQGEYQGRVLFKNYSLNDATITLHNIGFSDSGKYICKAVTFPLGNAQSSTTVTVLVEPTVSLIKGPDSLIDGGNETVAAICIAATGKPVAHIDWEGDLGEMESTTTSFPNETATIIS QYKLFPTRFARGRRITCVVKHPALEKDIRYSFILDIQYAPEVSVTGYDGNWFVGRKGVNLKCNADANPPPFKSVWSRLDGQWPDGLLASDNTLHFVHPLTFNYSGVYICKVTNSLGQRSDQKVIYISDPPTTTTLQPTIQWHPSTADIEDLATEPKKLPFPLSTLATIKDD (SEQ ID NO:8) Human CD113 extracellular domain, GENBANK® accession number NM_015480.3
[0160] Exemplary sequences of component Y include or consist of the following sequences: AEPHSLRYNLTVLSWDGSVQSGFLTEVHLDGQPFLRCDRQKCRAKPQGQWAEDVLGNKTWDRETRDLTGNGKDLRMTLAHIKDQKEGLHSLQEIRVCEIHEDNSTRSSQHFYYDGELFLSQNLETKEWTMPQSSRAQTLAMN VRNFLKEDAMKTKTHYHAMHADCLQELRRYLKSGVVLRRTVPPMVNVTRSEASEGNITVTCRASGFYPWNITLSWRQDGVSLSHDTQQWGDVLPDGNGTYQTWVATRICQGEEQRFTCYMEHSGNHSTHPVPSGKVLVLQSHW (SEQ ID NO:9) Human MICA (MHC-I polypeptide related sequence A) extracellular domain, GENBANK® Accession No. NM_000247.3
[0161] Leader sequence Exemplary sequences of leader sequences include or consist of the following sequences: MKWVTFISLLFLFSSAYS (SEQ ID NO: 10) Human albumin leader sequence
[0162] Hinge Exemplary sequences of the hinge include or consist of the following sequences: EPKSSDKTHTCPPCPAPELLGG (SEQ ID NO: 11) Human IgG hinge
[0163] Component Z2 Exemplary sequences of component Z2 include or consist of the following sequences: PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCAVSNKALPAPIEKTISKAK (SEQ ID NO: 12) IgG1
[0164] Component Z3 Exemplary sequences of component Z3 include or consist of the following sequences: GQPREPQVCTLPPSRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLSLSPGK (SEQ ID NO: 13) IgG1
[0165] Exemplary sequences of component A include or consist of the following sequences: [ka] Italics: human albumin leader sequence Wavy line: human PD-1 extracellular domain; Y domain Bold: IgG1 hinge region Double underline: IgG1 Z2 domain Bold line: IgG1 Z3 domain
[0166] Another exemplary sequence of component A comprises or consists of the following sequence: [ka] Italics: human albumin leader sequence Wavy line: high affinity human PD-1 extracellular domain; Y domain Bold: IgG1 hinge region Double underline: IgG1 Z2 domain Bold line: IgG1 Z3 domain
[0167] Another exemplary sequence of component A comprises or consists of the following sequence: [ka] Italics: human albumin leader sequence Wavy line: human CD112R extracellular domain; Y domain Bold: IgG1 hinge region Double underline: IgG1 Z2 domain Bold line: IgG1 Z3 domain
[0168] Another exemplary sequence of component A comprises or consists of the following sequence: [ka] Italics: human albumin leader sequence Wavy line: high affinity human TIGIT extracellular domain; Y domain Bold: IgG1 hinge region Double underline: IgG1 Z2 domain Bold line: IgG1 Z3 domain
[0169] Another exemplary sequence of component A comprises or consists of the following sequence: [ka] Italics: human albumin leader sequence Wavy line: human CD96 extracellular domain; Y domain Bold: IgG1 hinge region Double underline: IgG1 Z2 domain Bold line: IgG1 Z3 domain
[0170] Another exemplary sequence of component A comprises or consists of the following sequence: [ka] Italics: human albumin leader sequence Wavy line: human CD226 extracellular domain; Y domain Bold: IgG1 hinge region Double underline: IgG1 Z2 domain Bold line: IgG1 Z3 domain
[0171] Another exemplary sequence of component A comprises or consists of the following sequence: [ka] Italics: human albumin leader sequence Wavy line: human NECL2 extracellular domain; Y domain Bold: IgG1 hinge region Double underline: IgG1 Z2 domain Bold line: IgG1 Z3 domain
[0172] Another exemplary sequence of component A comprises or consists of the following sequence: [ka] Italics: human albumin leader sequence Wavy line: human CD113 extracellular domain; Y domain Bold: IgG1 hinge region Double underline: IgG1 Z2 domain Bold line: IgG1 Z3 domain
[0173] Another exemplary sequence of component A comprises or consists of the following sequence: [ka] Italics: human albumin leader sequence Wavy line: human MICA extracellular domain; Y domain Bold: IgG1 hinge region Double underline: IgG1 Z2 domain Bold line: IgG1 Z3 domain
[0174] [ka] Italics: human albumin leader sequence Bold: IgG1 hinge region Double underline: IgG1 Z2 domain Bold line: IgG1 Z3 domain
[0175] Component B Component B includes component X', component Z2', and component Z3'. In some embodiments, component X' includes a virus-derived peptide, a ligand-derived peptide, a receptor-derived peptide, or an HTS-selected peptide. In some embodiments, component X' includes at least a portion of PD-1, TIGIT, CD96, CD112R, CD113, CD155, CD111, CD112, MHC-I polypeptide-related sequence A (MICA), NKG2A (CD94), MICB, ULBP1-5, TIM-3, CD226, NECL2, CRTAM, CD80, CTLA-4, KIR2DL1 / 2 / 3, or CD48.
[0176] Component X' Exemplary sequences of component X' include or consist of the following sequences: WPPPGTGDVVVQAPTQVPGFLGDSVTLPCYLQVPNMEVTHVSQLTWARHGESGSMAVFHQTQGPSYSESKRLEFVAARLGAELRNASLRMFGLRVEDEGNYTCLFVTFPQGSRSVDIWLRVLAKPQNTAEVQKVQLTGEPVPMARCVSTGGRPPAQITWHS DLGGMPNTSQVPGFLSGTVTVTSLWILVPSSQVDGKNVTCKVEHESFEKPQLLTVNLTVYYPPEVSISGYDNNWYLGQNEATLTCDARSNPEPTGYNWSTTMGPLPPFAVAQGAQLLIRPVDKPINTTLICNVTNALGARQAELTVQVKEGPPSEHSGMSRN (SEQ ID NO:24) Human CD155 (poliovirus receptor, PVR) extracellular domain, GENBANK® accession number NM_006505.5
[0177] Exemplary sequences of component X' include or consist of the following sequences: MMTGTIETTGNISAEKGGSIILQCHLSSTTAQVTQVNWEQQDQLLAICNADLGWHISPSFKDRVAPGPGLGLTLQSLTVNDTGEYFCIYHTYPDGTYTGRIFLEVLESSVAEHGARFQIP (SEQ ID NO: 25) Human TIGIT (Ig domain-ITIM domain-containing T cell immunoreceptor) extracellular domain, GENBANK® accession number NM_173799.4
[0178] Exemplary sequences of component X' include or consist of the following sequences: LEDGYKVEVGKNAYLPCSYTLPTSGTLVPMCWGKGFCPWSQCTNELLRTDERNVTYQKSSRYQLKGDLNKGDVSLIIKNVTLDDHGTYCCRIQFPGLMNDKKLELKLDIKAAKVTPAQTAHGDSTTASPRTLTTERNGSETQTLVTLHNNNGTKISTWADEIKDSGETIR (SEQ ID NO: 26) Mouse Tim-3 extracellular domain, GENBANK® accession number NM_134250.2 Mouse TIM-3 has good binding affinity to human galactin-9.
[0179] Exemplary sequences of component X' include or consist of the following sequences: PIIVEPHVTAVWGKNVSLKCLIEVNETITQISWEKIHGKSSQTVAVHHPQYGFSVQGEYQGRVLFKNYSLNDATITLHNIGFSDSGKYICKAVTFPLGNAQSSTTVTVLVEPTVSLIKGPDSLIDGGNETVAAICIAATGKPVAHIDWEGDLGEMESTTTSFPNETATIIS QYKLFPTRFARGRRITCVVKHPALEKDIRYSFILDIQYAPEVSVTGYDGNWFVGRKGVNLKCNADANPPPFKSVWSRLDGQWPDGLLASDNTLHFVHPLTFNYSGVYICKVTNSLGQRSDQKVIYISDPPTTTTLQPTIQWHPSTADIEDLATEPKKLPFPLSTLATIKDD (SEQ ID NO:27) Human CD113 extracellular domain, GENBANK® accession number NM_015480.3
[0180] Leader sequence Exemplary sequences of leader sequences include or consist of the following sequences: MKWVTFISLLFLFSSAYS (SEQ ID NO: 10) Human albumin leader sequence
[0181] Hinge Exemplary sequences of the hinge include or consist of the following sequences: EPKSSDKTHTCPPCPAPELLGG (SEQ ID NO: 11) Human IgG hinge
[0182] Component Z2' Exemplary sequences of component Z2' include or consist of the following sequences: PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCAVSNKALPAPIEKTISKAK (SEQ ID NO: 12) IgG1
[0183] Component Z3' Exemplary sequences of component Z3' include or consist of the following sequences: GQPREPQVCTLPPSRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLSLSPGK (SEQ ID NO: 13) IgG1
[0184] Exemplary sequences of component B include or consist of the following sequences: [ka] Italics: human albumin leader sequence Wavy line: human CD155 (poliovirus receptor, PVR) extracellular domain; X' domain Bold: IgG1 hinge region Double underline: IgG1 Z'2 domain Bold line: IgG1 Z'3 domain
[0185] Another exemplary sequence of component B comprises or consists of the following sequence: [ka] Italics: human albumin leader sequence Wavy line: human TIGIT (Ig domain-ITIM domain-containing T cell immunoreceptor) extracellular domain; X' domain Bold: IgG1 hinge region Double underline: IgG1 Z'2 domain Bold line: IgG1 Z'3 domain
[0186] Another exemplary sequence of component B comprises or consists of the following sequence: [ka] Italics: human albumin leader sequence Wavy line: mouse TIM-3 extracellular domain; X' domain Bold: IgG1 hinge region Double underline: IgG1 Z'2 domain Bold line: IgG1 Z'3 domain
[0187] Another exemplary sequence of component B comprises or consists of the following sequence: [ka] Italics: human albumin leader sequence Wavy line: human CD113 extracellular domain; X' domain Bold: IgG1 hinge region Double underline: IgG1 Z'2 domain Bold line: IgG1 Z'3 domain
[0188] [ka] Italics: human albumin leader sequence Bold: IgG1 hinge region Double underline: IgG1 Z'2 domain Bold line: IgG1 Z'3 domain
[0189] Component B including component Z1' In some embodiments, component B further comprises component Z1'. Thus, in some embodiments, component B comprises component X', component Z1', component Z2', and component Z3'.
[0190] In some embodiments, component X' comprises a virus-derived peptide, a ligand-derived peptide, a receptor-derived peptide, or an HTS-selected peptide. In some embodiments, component X' comprises at least a portion of PD-1, TIGIT, CD96, CD112R, CD113, CD155, CD111, CD112, MHC-I polypeptide-related sequence A (MICA), NKG2A (CD94), MICB, ULBP1-5, TIM-3, CD226, NECL2, CRTAM, CD80, CTLA-4, KIR2DL1 / 2 / 3, or CD48. In other embodiments, component X' comprises at least a portion of CD155, TIGIT, TIM-3, or CD113.
[0191] Component X' Exemplary sequences of component X' include or consist of the following sequences: LGASWHRPDKCCLGYQKRPLPQVLLSSWYPTSQLCSKPGVIFLTKRGRQVCADKSKDWVKKLMQQLPVTAR (SEQ ID NO: 37) vMIPII, GENBANK® Accession No. YP_001129362
[0192] Exemplary sequences of component X' include or consist of the following sequences: LGASWHRPDKCCLGYQKRPLP (SEQ ID NO:38) V1
[0193] Exemplary sequences of component X' include or consist of the following sequences: LGASWHRPDKCALGYQKRPLP (SEQ ID NO:39) V1Δ
[0194] Exemplary sequences of component X' include or consist of the following sequences: LGASWHRPDACALGYQKRPLP (SEQ ID NO: 40) V1Δmut
[0195] Exemplary sequences of component X' include or consist of the following sequences: LGASWHRPDKCCLGYQKRPLPQVLLSSWYPTSQL (SEQ ID NO: 41) Vp1
[0196] Exemplary sequences of component X' include or consist of the following sequences: LGASWHRPDKCALGYQKRPLPQVLLSSWYPTSQL (SEQ ID NO: 42) Vp1Δ
[0197] Exemplary sequences of component X' include or consist of the following sequences: LGASWHRPDACALGYQKRPLPQVLLSSWYPTSQL (SEQ ID NO: 43) Vp1Δmut
[0198] Leader sequence Exemplary sequences of leader sequences include or consist of the following sequences: MKWVTFISLLFLFSSAYS (SEQ ID NO: 10) Human albumin leader sequence
[0199] Component Z1' Exemplary sequences of component Z1' include or consist of the following sequences: SSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVX (SEQ ID NO:45)
[0200] Hinge Exemplary sequences of the hinge include or consist of the following sequences: EPKSSDKTHTCPPCPAPELLGG (SEQ ID NO:11)
[0201] Component Z2' Exemplary sequences of component Z2' include or consist of the following sequences: PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCAVSNKALPAPIEKTISKAK (SEQ ID NO:12)
[0202] Component Z3' Exemplary sequences of component Z3' include or consist of the following sequences: GQPREPQVYTLPPSRCELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLSLSPGK (SEQ ID NO:48)
[0203] Exemplary sequences of component B include or consist of the following sequences: [ka] Italics: human albumin leader sequence Wavy line: vMIPII Thick wavy lines: amino acid differences between V1, V1Δ, and V1Δmut Bold line: CH' Bold: IgG1 hinge region Double underline: IgG1 Z'2 domain Bold line: IgG1 Z'3 domain
[0204] Exemplary sequences of component B include or consist of the following sequences: [ka] Italics: human albumin leader sequence Wavy line: V1 (V1 is the first 21 amino acids of VMIPII) Thick wavy lines: amino acid differences between V1, V1Δ, and V1Δmut Bold line: CH' Bold: IgG1 hinge region Double underline: IgG1 Z'2 domain Bold line: IgG1 Z'3 domain
[0205] Exemplary sequences of component B include or consist of the following sequences: [ka] Italics: human albumin leader sequence Wavy line: V1Δ (V1Δ is V1 with a C to A mutation at amino acid 11 that enhances dimerization of two V1 peptides) Thick wavy lines: amino acid differences between V1, V1Δ, and V1Δmut Bold line: CH' Bold: IgG1 hinge region Double underline: IgG1 Z'2 domain Bold line: IgG1 Z'3 domain
[0206] Exemplary sequences of component B include or consist of the following sequences: [ka] Italics: human albumin leader sequence Wavy line: V1Δmut (V1Δmut has the same C to A mutation at amino acid 11 as V1, but adds a K to A mutation at amino acid 9 that prevents receptor binding). Thick wavy lines: amino acid differences between V1, V1Δ, and V1Δmut Bold line: CH' Bold: IgG1 hinge region Double underline: IgG1 Z'2 domain Bold line: IgG1 Z'3 domain
[0207] Exemplary sequences of component B include or consist of the following sequences: [ka] Italics: human albumin leader sequence Wavy line: Vp1 (Vp1 is the first 34 amino acids of vMIPII) Thick wavy lines: amino acid differences between V1, V1Δ, and V1Δmut Bold line: CH' Bold: IgG1 hinge region Double underline: IgG1 Z'2 domain Bold line: IgG1 Z'3 domain
[0208] Exemplary sequences of component B include or consist of the following sequences: [ka] Italics: human albumin leader sequence Wavy line: Vp1Δ Thick wavy lines: amino acid differences between V1, V1Δ, and V1Δmut Bold line: CH' Bold: IgG1 hinge region Double underline: IgG1 Z'2 domain Bold line: IgG1 Z'3 domain
[0209] [ka] Italics: human albumin leader sequence Wavy line: Vp1Δmut Thick wavy lines: amino acid differences between V1, V1Δ, and V1Δmut Bold line: CH' Bold: IgG1 hinge region Double underline: IgG1 Z'2 domain Bold line: IgG1 Z'3 domain
[0210] Component C In some embodiments, the fusion protein further comprises a component C, which comprises component X and component C. L ' is included.
[0211] Component X Exemplary sequences of component X include or consist of the following sequences: LGASWHRPDKCCLGYQKRPLPQVLLSSWYPTSQLCSKPGVIFLTKRGRQVCADKSKDWVKKLMQQLPVTAR (SEQ ID NO: 37) vMIPII, GENBANK® Accession No. YP_001129362
[0212] Exemplary sequences of component X include or consist of the following sequences: LGASWHRPDKCCLGYQKRPLP (SEQ ID NO:38) V1
[0213] Exemplary sequences of component X include or consist of the following sequences: LGASWHRPDKCALGYQKRPLP (SEQ ID NO:39) V1Δ
[0214] Exemplary sequences of component X include or consist of the following sequences: LGASWHRPDACALGYQKRPLP (SEQ ID NO: 40) V1Δmut
[0215] Exemplary sequences of component X include or consist of the following sequences: LGASWHRPDKCCLGYQKRPLPQVLLSSWYPTSQL (SEQ ID NO: 41) Vp1
[0216] Exemplary sequences of component X include or consist of the following sequences: LGASWHRPDKCALGYQKRPLPQVLLSSWYPTSQL (SEQ ID NO: 42) Vp1Δ
[0217] Exemplary sequences of component X include or consist of the following sequences: LGASWHRPDACALGYQKRPLPQVLLSSWYPTSQL (SEQ ID NO: 43) Vp1Δmut
[0218] In some embodiments, component X and component X' are the same. In other embodiments, component X is different from component X'.
[0219] Leader sequence Exemplary sequences of leader sequences include or consist of the following sequences: MKWVTFISLLFLFSSAYS (SEQ ID NO: 10) Human albumin leader sequence
[0220] Component C L ' Component C L Exemplary sequences of ' include or consist of the following sequences: KRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO:64)
[0221] Exemplary sequences of component C include or consist of the following sequences: [ka] Italics: human albumin leader sequence Wavy line: vMIPII Thick wavy lines: amino acid differences between V1, V1Δ, and V1Δmut Bold line: CL'
[0222] Exemplary sequences of component C include or consist of the following sequences: [ka] Italics: human albumin leader sequence Wavy line: V1 Thick wavy lines: amino acid differences between V1, V1Δ, and V1Δmut Bold line: CL'
[0223] Exemplary sequences of component C include or consist of the following sequences: [ka] Italics: human albumin leader sequence Wavy line: V1Δ Thick wavy lines: amino acid differences between V1, V1Δ, and V1Δmut Bold line: CL'
[0224] Exemplary sequences of component C include or consist of the following sequences: [ka] Italics: human albumin leader sequence Wavy line: V1Δmut Thick wavy lines: amino acid differences between V1, V1Δ, and V1Δmut Bold line: CL'
[0225] Exemplary sequences of component C include or consist of the following exemplary sequences: [ka] Italics: human albumin leader sequence Wavy line: Vp1 Thick wavy lines: amino acid differences between V1, V1Δ, and V1Δmut Bold line: CL'
[0226] Exemplary sequences of component C include or consist of the following sequences: [ka] Italics: human albumin leader sequence Wavy line: Vp1Δ Thick wavy lines: amino acid differences between V1, V1Δ, and V1Δmut Bold line: CL'
[0227] Exemplary sequences of component C include or consist of the following sequences: [ka] Italics: human albumin leader sequence Wavy line: Vp1Δmut Thick wavy lines: amino acid differences between V1, V1Δ, and V1Δmut Bold line: CL'
[0228] Component D In some embodiments, the fusion protein further comprises component D, which is a component of component Q and component C. L In some embodiments, component Q comprises at least a portion of PD-1, TIGIT, CD96, CD112R, CD113, CD155, CD111, CD112, MHC-I polypeptide-associated sequence A (MICA), NKG2A (CD94), MICB, ULBP1-5, TIM-3, CD226, NECL2, CRTAM, CD80, CTLA-4, KIR2DL1 / 2 / 3, or CD48.
[0229] Exemplary sequences of component Q include or consist of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, or 9. In some embodiments, component Q and component Y are the same. In other embodiments, component Q is different from component Y.
[0230] Component C L Component C L Exemplary sequences include or consist of the following sequences: KRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO:64)
[0231] Fusion protein construction In some embodiments of the fusion proteins of the invention, when prepared by recombinant techniques described elsewhere herein, the coding sequences of the components of component A are fused together in frame, either directly or via a linker. As used herein, the term "directly" refers to fusing two components without a peptide linker between them (i.e., the codons encoding component Y, component Z2, and component Z3 are contiguous in the expression construct). As used herein, "fused in frame" means that expression of the fusion coding sequences results in a fusion protein that includes all of the polypeptide components, e.g., in some embodiments, component A includes all of the polypeptide components of component Y, component Z2, and component Z3 in frame.
[0232] In some embodiments of the fusion proteins of the invention, when prepared by recombinant techniques described elsewhere herein, the coding sequences of the components of component B are fused together in frame, either directly or via a linker. In some embodiments, in the expression construct of component B, the codons encoding component X', component Z2 and component Z3' are contiguous. In other embodiments, in the expression construct of component B, the codons encoding component X', component Z1', component Z2 and component Z3' are contiguous. In some embodiments, component B comprises all of the polypeptide components of component X', component Z2 and component Z3' in frame. In other embodiments, component B comprises all of the polypeptide components of component X', component Z1', component Z2' and component Z3' in frame.
[0233] In some embodiments of the fusion proteins of the invention, when prepared by recombinant techniques described elsewhere herein, the coding sequences of the components of component C are fused together in frame, either directly or via a linker. In some embodiments, in the expression construct of component C, component X and component C L In some embodiments, component C is a sequence of codons encoding component X and component C'. L ' in frame.
[0234] In some embodiments, any component A and any component B can be combined and mixed together. In some exemplary embodiments of the fusion protein of the present invention, component A and component B are as shown in Table 1. In some embodiments, component A and component B in Table 1 can be combined and mixed together or with additional component A and component B options. The above additional options can also be combined and mixed together. The additional options of component A or component B can include at least a portion of PD-1, TIGIT, CD96, CD112R, CD113, CD155, CD111, CD112, MHC-I polypeptide-related sequence A (MICA), NKG2A (CD94), MICB, ULBP1-5, TIM-3, CD226, NECL2, CRTAM, CD80, CTLA-4, KIR2DL1 / 2 / 3, or CD48.
[0235] In some embodiments, the fusion protein comprises component A and hFcB. In some embodiments, the fusion protein comprises component B and hFcA.
[0236] In some exemplary embodiments, one component of the fusion protein blocks an inhibitory receptor, while the other two components of the fusion protein each stimulate a distinct activating receptor. In preferred embodiments, these three receptors are co-localized on the surface of the same immune effector cell, e.g., an NK cell, and the three interactions of the fusion protein act to reinforce each other, combining blockage of inhibitory pathways and stimulation of activating receptors, all three interactions working together to activate the NK cell.
[0237] In another exemplary embodiment, two of the fusion protein components each block a distinct inhibitory receptor, and the other fusion protein component stimulates an activating receptor. In a preferred embodiment, these three receptors are co-localized on the surface of the same immune effector cell, e.g., an NK cell, and the three interactions of the fusion protein act to functionally reinforce each other, combining blockage of inhibitory pathways and stimulation of activating receptors, all three interactions working together to trigger NK cell activation.
[0238] In yet another exemplary embodiment, the three components of the fusion protein each stimulate an activating receptor. In a preferred embodiment, these three receptors are co-localized on the surface of the same immune effector cell, e.g., an NK cell, and the three interactions of the fusion protein that are all activating receptor stimulaters act to functionally reinforce each other, with all three interactions acting in concert to cause NK cell activation.
[0239] For NK cells, the activating receptor in the above embodiment is an Fc receptor that causes activation of NK cells and promotes antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). γ It may be the RIIIa receptor.
[0240] [Table 1]
[0241] In some exemplary embodiments, the fusion protein includes component B and component C. In some embodiments, any component B and any component C can be mixed in combination with each other. In some embodiments, components B and C are as shown in Table 2. In some embodiments, each row of Table 2 represents a combination of components B and C in a fusion protein.
[0242] [Table 2]
[0243] In some embodiments, components A and B are linked via knob-into-hole interactions (KiH) that are stabilized by a disulfide bond. S-S ) are joined together. In some embodiments, component A contains the mutations Y349C and T366W (e.g., SEQ ID NO:29) and component B contains the mutations D356C, T366S, L368A, and Y407V (e.g., SEQ ID NO:30) ("knobs-into-holes" mutations), which allow forced dimerization of component A with component B. Components Z1, Z2, and Z3 are based on the polypeptide amino acid backbone of the CH1, CH2, and CH3 domains of human IgG1, respectively. The positions of the mutations and changes within these component chains are defined by the Kabat numbering system (Johnson, G, and Wu, TT, (2011), Nucleic Acids Res. 28(1):214-18) and are based on the wild-type human IgG1 sequence.
[0244] [ka] Wavy line: IgG1 Z1 domain Bold: IgG1 hinge region Double underline: IgG1 Z2 domain Bold line: IgG1 Z3 domain
[0245] In some embodiments, component A comprises or consists of the following sequence: Y349C and T366W. [ka] Wavy line: IgG1 Z1 domain (SEQ ID NO: 67) (see e.g. FIG. 1a) Bold: IgG1 hinge region (SEQ ID NO: 68) S *: This mutation was added to the hinge region to remove an unpaired cysteine (C) that may bind differently to another cysteine compared to the wild type. Double underlined: IgG1 Z2 domain (SEQ ID NO:69) A ** : Mutations added to reduce C1q binding (see Figure 1a for an example) Bold line: IgG1 Z3 domain (SEQ ID NO: 44) L *** and S *** : Mutations added to increase FcRn binding (see Figure 1a for an example)
[0246] In some embodiments, component B comprises or consists of the following sequences: D356C, T366S, L368A and Y407V. [ka] Wavy line: IgG1 Z1' domain
[0247] The components shown in Tables 1 and 2 are examples and are not intended to be limiting.
[0248] In some exemplary embodiments, one component of the fusion protein interferes with a receptor on a tumor cell that contributes to the tumorigenicity and / or metastatic potential of the tumor cell, a second component of the fusion protein interferes with a checkpoint inhibitor on the tumor cell, and a third component of the fusion protein stimulates an activating receptor on an immune effector cell. Without wishing to be bound by theory, the fusion protein acts to form a molecular bridge between the immune effector cell and the target tumor cell, and the second and third components of the fusion protein act to reinforce each other and cooperate by coordinating the interference with the checkpoint inhibitor and the stimulation of an activating receptor on the immune effector cell, e.g., NK cell, resulting in the activation of the immune effector cell.
[0249] In a preferred embodiment, the first component of the fusion protein acts to block chemokine receptors (e.g., CXCR4 and / or CXCR7) (through binding of the vMIPII or V1 peptide or a derivative thereof in the fusion protein), which immobilizes tumor cells and impairs their migration, invasiveness, metastasis, and other tumorigenic properties. The second component of the fusion protein acts to block checkpoint inhibitors, e.g., PD-L1 and / or PD-L2, on tumor cells (through binding of PD1 or a derivative thereof in the fusion protein), which impairs the inhibition of tumor-directed immune effector cells, e.g., NK cells. The third component of the fusion protein acts to block checkpoint inhibitors, e.g., PD-L1 and / or PD-L2, on tumor cells (through binding of the Fc or V1 peptide or a derivative thereof in the fusion protein), which impairs the inhibition of tumor-directed immune effector cells, e.g., NK cells. γ or a derivative thereof) to an activating receptor on the same immune effector cell, e.g., Fc γ It stimulates the RIIIa receptor, thereby causing activation of NK cells and promoting ADCC and ADCP. A beneficial feature of the above embodiment is that the same fusion protein also coordinately regulates other immune cells besides NK cells with a net anti-tumor effect (see FIG. 5).
[0250] In some exemplary embodiments, one component of the fusion protein blocks a checkpoint inhibitor on a tumor or other cell, while the other two components each stimulate a distinct activating receptor on an immune effector cell. When a checkpoint inhibitor is present on a tumor cell, the fusion protein acts in effect to form a molecular bridge between the immune effector cell and the target tumor cell. Furthermore, the three interactions of the fusion protein, the combination of blocking checkpoint inhibition pathways and stimulating activating receptors, act to functionally reinforce each other, and all three interactions cooperate to cause the activation of immune effector cells, such as NK cells. In a preferred embodiment, the checkpoint inhibitors blocked by the fusion protein consist of PD-L1, PD-L2, CD113, CD112, CD155, or CD111, and the two activating receptors that the fusion protein co-stimulates are Fc receptors on NK cells. γ These are the RIIIa receptor and 4-1BB (see FIG. 6).
[0251] In some exemplary embodiments, one component of the fusion protein blocks a checkpoint inhibitor on a tumor cell or other cell, a second component of the fusion protein blocks a co-inhibitory receptor for the same or a different checkpoint inhibitor on an immune effector cell, and a third component of the fusion protein stimulates an activating receptor on the immune effector cell. When a checkpoint inhibitor is present on a tumor cell, the fusion protein effectively acts to form a molecular bridge between the immune effector cell and the target tumor cell, and the three interactions of the fusion protein, the combination of blocking a checkpoint inhibition pathway and stimulating an activating receptor, act to functionally reinforce each other, and all three interactions act in concert to cause activation of immune effector cells, such as NK cells. In a preferred embodiment, the checkpoint inhibitor that the first component of the fusion protein blocks consists of PD-L1, PD-L2, CD113, CD112, CD155, or CD111, the co-inhibitory receptor on the NK cell that the fusion protein blocks consists of PD-1, TIGIT, CD96, or CD112R, and the activating receptor that the fusion protein stimulates consists of Fc receptor 1 on the same NK cell. γ The RIIIa receptor (see FIG. 7).
[0252] In some exemplary embodiments, one component of the fusion protein blocks an inhibitory "don't eat me" signaling receptor on M1-type tumor-associated macrophages, thereby relieving the antitumor phagocytic and other activities of the receptor, and the other two components of the fusion protein each stimulate a distinct activating receptor on the tumor-associated macrophages. The three interactions of the fusion protein, which are the combination of blocking macrophage inhibitory pathways and stimulating distinct activating receptors on the macrophages, act to functionally reinforce each other, and all three interactions cooperate to activate tumor-associated macrophages and promote their antitumor functions. In a preferred embodiment, the "don't eat me" signaling receptor that the first component of the fusion protein blocks is SIRPα, and the activating receptors that the fusion protein stimulates are CD40 and Fcα on the same macrophages. γThe RIIIa receptor (see FIG. 8, left panel).
[0253] In some exemplary embodiments, one component of the fusion protein blocks an inhibitory "don't eat me" signaling receptor on M1-type tumor-associated macrophages, thereby reversing the anti-tumor phagocytic and other activities of said receptor, a second component of the fusion protein blocks a distinct inhibitory receptor on the macrophage, and a third component of the fusion protein stimulates an activating receptor on the tumor-associated macrophage. The three interactions of the fusion protein, the combination of blocking two macrophage inhibitory pathways and stimulating an activating receptor on the macrophage, act to functionally reinforce each other, and all three interactions cooperate to cause activation and / or anti-tumor effector functions of tumor-associated macrophages. In a preferred embodiment, the "don't eat me" signaling receptor blocked by the first component of the fusion protein is SIRPα, the inhibitory receptor blocked by the second component of the fusion protein is PD-1, and the activating receptor stimulated by the fusion protein is Fcα. γ The RIIIa receptor (see Figure 8, right panel).
[0254] A preferred embodiment of the fusion protein of the present invention comprises a cytokine or a portion or derivative thereof, which may be incorporated into component A, component B, component C, and / or component D. The cytokines include a wide range of cytokines well known to those skilled in the art, which are classified into many different classes, e.g., interleukins, tumor necrosis factors, interferons, colony stimulating factors, and others, and which have been implicated in a variety of functions with an array of activating or inhibitory properties, e.g., adaptive immunity, pro-inflammatory signaling, anti-inflammatory signaling, stem cell modification and differentiation, chemotaxis, phagocytosis, cytotoxicity, and antiviral effects, and which are associated with a range of immune and non-immune cell targets, e.g., B cells, T cells, NK cells, macrophages / monocytes, dendritic cells, bone marrow stromal cells, stem cells, fibroblasts, endothelial cells, and epithelial cells. Preferred embodiments include cytokines associated with adaptive immunity (e.g., IL-2, IL-4, IL-7, IL-9, IL-15, IL-21, GM-CSF), cytokines associated with pro-inflammatory signaling [e.g., IL-1 family (IL-1, IL-18, IL-33, IL-36), IL-6 family (IL-6, IL-11, IL-31, CNTF, CT-1, LIF, OPN, OSM), TNFα family (TNFα, TNFβ, BAFF, APRIL), IL-17 family (IL-17A-F, IL-17B-F, IL-17C-F, IL-17D-F, IL-17F ... -25), type I IFN family (IFNα, IFNβ, IFNκ, limitin), type II IFN family (IFNγ), and type III IFN family (IFNλ1 / IL-29, IFNλ2 / IL-28A, IFNλ3 / IL-28B)], and cytokines involved in anti-inflammatory signaling [IL-12 family (IL-12, IL-23, IL-27, IL-35) and IL-10 family (IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28, IL-29)].See Turner, Mark D., "Cytokines and Chemokines: At the Crossroads of Cell Signaling and Inflammatory Disease," Biochimica et Biophysica Acta, 1843 (2014), 2563-2582.
[0255] vMIP-II In some embodiments, a component of the fusion protein of the invention may include vMIP-II or a variant thereof. Viral macrophage inflammatory protein-II (vMIP-II) is a chemokine that interacts with CC and CXC chemokine receptors, including CCR5 and CXCR4 chemokine receptors. CCR5 and CXCR4 are the major coreceptors required for cell entry of human immunodeficiency virus (HIV-1). CXCR4 can also be found on cancer cells, e.g., on tumor cells. vMIP-II (Moore, PS et al., Science 274:1739-1744, 1996), a chemokine encoded by human herpesvirus 8 (HHV-8), exhibits multiple interactions with both CC and CXC chemokine receptors and interferes with HIV-1 entry via CCR3, CCR5, and CXCR4. See U.S. Patent Application Publication No. 2003 / 0220482, which is incorporated by reference in its entirety. vMIP-II also binds to CXCR7, which, like CXCR4, has been implicated in tumorigenesis. V1 (amino acids 1-21 of vMIP-II) and its related DV1 (D amino acid isomer) exhibit antagonist activity against CXCR4 and CXCR7, but not against CCR5.
[0256] vMIP inhibits binding of the natural ligand CXCL12. In some embodiments, Δ refers to a mutation at amino acid 12 that causes dimerization between two peptides, component B and component C. In some embodiments, Δmut refers to a mutation at amino acid 10 that prevents binding of the peptides and serves as a negative control.
[0257] PD-1 In some embodiments, a component of the fusion protein of the invention may include PD-1 or a variant thereof. PD-1 (programmed cell death protein 1), also known as CD279, is a protein on the surface of cells that plays a role in regulating the immune system's response to the cells. PD-1 downregulates the immune system and promotes self-tolerance by suppressing T cell inflammatory activity. Without wishing to be bound by theory, PD-1 acts as an immune checkpoint through at least two mechanisms. PD-1 promotes apoptosis of antigen-specific T cells in lymph nodes. PD-1 also reduces apoptosis of regulatory T cells. PD-1 binds to the ligands PD-L1 and PD-L2, which are members of the B7 family. PD-L1 and PD-L2 are expressed on the surface of some tumor cells. PD-L1 expressed on tumor cells binds to PD-1 on effector T cells and NK cells and inhibits the function of these cells. Thus, PD-L1 expressed on tumor cells inhibits the anti-tumor activity of effector T cells.
[0258] In some embodiments, the PD-1 mutant of the fusion protein of the invention is a high affinity PD-1. Native PD-1 has a relatively low affinity for its ligands, PD-L1 and PD-L2. A high affinity mutant of the PD-1 ectodomain would function as a more competitive antagonist for the PD-1 ligand. PD-1 contact residues between human PD-1 and PD-L1 were mutated and then evaluated for binding. The high affinity PD-1 described herein has 10 amino acid mutations that achieve a greater than 10,000-fold increase in affinity for PD-L1. For further details, see Maute et al., PNAS 112(47):6506-6514, 2015.
[0259] CD112R In some embodiments, a component of the fusion protein of the invention may include CD112R or a variant thereof. CD112R is expressed on T cells and NK cells and inhibits activation responses. CD112, which is widely expressed on antigen presenting cells and tumor cells, is a ligand for CD112R. CD112R competes with the co-inhibitory receptor CD226 for binding to CD112. Without wishing to be bound by theory, disruption of the CD112R-CD112 interaction may increase T cell responses. Human CD112R contains a single extracellular IgV domain. The CD112R fusion protein variants described herein are composed of the entire ectodomain of human CD112R bound to the hinge, CH2, and CH3 domains of human IgG1. CD112R and variants may bind to their ligand, CD112, and act as competitive antagonists to the native CD112R on NK cells and T cells to inhibit inhibitory signaling.
[0260] CD113 In some embodiments, a component of the fusion protein of the invention may include CD113 or a variant thereof. CD113, also known as poliovirus receptor-related protein 3 (PVRL3) or nectin-3, is a member of the immunoglobulin superfamily that forms adherens junctions. CD113 has been shown to interact with, but not limited to, MLLT4, PARD3, and PTPRM. CD113 also binds to TIGIT, CD111, CD112, CD155, and itself. The CD113 fusion protein variants described herein are composed of the entire extracellular domain of native human CD113 linked to the hinge, CH2, and CH3 domains of human IgG1. CD113-containing fusion proteins may act as competitive antagonists to native TIGIT on NK and T cells to inhibit inhibitory signaling. Alternatively, CD113 fusion proteins may bind to CD112, CD155, and / or CD111 and disrupt their binding to the inhibitory receptors CD112R, TIGIT, and CD96, respectively, restoring NK and T cell cytotoxicity and cytokine production.
[0261] MICA In some embodiments, a component of the fusion protein of the invention may comprise MHC class I polypeptide-related sequence A (MICA) or a variant thereof. MICA is a cell surface glycoprotein encoded by the MICA gene located within the MHC locus. MICA does not bind β2 microglobulin or peptides that traditional MHC class I molecules bind. Without wishing to be bound by theory, MICA may act as a stress-induced ligand for the NKG2D receptor. MICA is broadly recognized by NK cells, γδ T cells, and CD8+αβ T cells that express NKG2D on their cell surface. Effector cytolytic responses of T cells and NK cells against tumor cells expressing MICA are initiated as a result of NKG2D-MICA binding. In some embodiments, the MICA variant is composed of the entire MICA ectodomain linked to the hinge, CH2, and CH3 domains of human IgG1. MICA stimulation of NKG2D signaling on NK cells and cytotoxic T cells is a key mediator of antitumor activity.
[0262] CD155 In some embodiments, a component of the fusion protein of the invention may comprise CD155 or a variant thereof. CD155 is a type I transmembrane glycoprotein of the immunoglobulin superfamily. In humans, CD155 is encoded by the poliovirus receptor (PVR) gene. CD155 is involved in the assembly of cell-cell adherens junctions between epithelial cells. The ectodomain of CD155 is involved in cell adhesion to the extracellular matrix molecule vitronectin, while its intracellular domain interacts with the dynein light chain Tctex-1 / DYNLT1. CD155 also binds to the NK cell inhibitory receptors TIGIT and CD96, and restricts the NK cell cytotoxicity and activation receptor CD226 (DNAM-1). CD155 ectodomain-containing fusion proteins may bind to TIGIT or CD96 on NK cells and T cells, and act as competitive antagonists against endogenous CD155 expressed by tumor cells or antigen-presenting cells (APCs). CD155-containing fusion proteins may also bind to the costimulatory receptor CD226 and induce NK cell-mediated lysis of tumor targets.
[0263] TIGIT In some embodiments, the components of the fusion protein of the present invention may include TIGIT or a variant thereof. In some embodiments, TIGIT is mouse TIGIT. In other embodiments, TIGIT is human TIGIT. In some embodiments, the TIGIT variant comprises the entire TIGIT extracellular IgV-like domain linked to the hinge, CH2, and CH3 domains of human IgG1.
[0264] TIGIT, also known as Ig domain-ITIM domain-containing T cell immunoreceptor, is an immunoreceptor present on some T cells and NK cells. TIGIT is also known as WUCAM or Vstm3. TIGIT binds with high affinity to CD155 (PVR) on cells such as dendritic cells (DCs) and macrophages, and with lower affinity to CD112 (PVRL2). TIGIT is a checkpoint inhibitor and is overexpressed on tumor antigen-specific (TA-specific) CD8+ T cells and CD8+ tumor infiltrating lymphocytes (TILs) from individuals with cancer, e.g., melanoma. Without wishing to be bound by theory, disruption of TIGIT may lead to increased cell proliferation, cytokine production, and degranulation of tumor antigen-specific CD8+ T cells and TIL CD8+ T cells. TIGIT-containing fusion proteins may bind to its receptors, CD155 (PVR) and CD112 (PVRL2), and disrupt their interaction with TIGIT on NK cells. Disruption of the interaction of TIGIT with its ligands on cancer cells restores NK cell cytotoxic activity and cytokine production.
[0265] TIM-3 In some embodiments, a component of the fusion protein of the invention may include TIM-3 or a variant thereof. T cell immunoglobulin and mucin domain-containing protein-3 (TIM-3), also known as Hepatitis A virus cellular receptor 2 (HAVCR2), is a protein encoded by the HAVCR2 gene in humans. HAVCR2 is a cell surface molecule expressed on IFNγ-producing CD4+Th1 cells and CD8+Tc1 cells. Expression of TIM-3 has also been detected on Th17 cells, regulatory T cells, and innate immune cells (dendritic cells, NK cells, monocytes). TIM-3 is an immune checkpoint and is involved in T cell exhaustion. Without wishing to be bound by theory, TIM-3 is upregulated in tumor infiltrating lymphocytes (TILs) in several types of cancer, including but not limited to lung cancer, gastric cancer, head and neck cancer, Schwannoma, melanoma, and follicular B-cell non-Hodgkin's lymphoma. In some embodiments, the TIM-3 variant comprises the entire TIM-3 ectodomain, including the N-terminal IgV-like domain and linked to the hinge, CH2, and CH3 domains of human IgG1. TIM-3-containing fusion proteins bind to its natural ligands galectin-9, cerecam-1, and phosphatidylserine and may disrupt their interaction with endogenous TIM-3 expressed on NK cells, T cells, and APCs, reversing T cell exhaustion and restoring NK cell cytotoxicity and cytokine production.
[0266] Tumor cell receptor targeting In some embodiments, the fusion protein or one or more components thereof bind to a tumor cell receptor target. In some embodiments, the fusion protein or one or more components thereof interfere with binding of a ligand to a tumor cell receptor target. In some embodiments, tumor cell receptor targets include, but are not limited to, chemokine receptors, notch receptors, immune checkpoint inhibitors, and tumor vasculature ligands and receptors. In some embodiments, chemokine receptors include CXCR4, CCR10, or CCR7. In some embodiments, immune checkpoint inhibitors include PD-L1 or PD-L2. In some embodiments, tumor vasculature targets include ανβ3, ανβ5, CD13 (aminopeptidase N), a target of NGF motif peptide, or Tie2 (receptor for angiopoietin-2).
[0267] Immune Cell Receptor Targeting In some embodiments, the immune cell receptor target is CD40. In some embodiments, the fusion protein, or one or more components thereof, comprises an agonistic CD40 scFv. In other embodiments, the immune cell receptor target is SIRPα. In some embodiments, the fusion protein, or one or more components thereof, comprises an antagonistic SIRPα peptide. In some embodiments, the immune cell receptor target is 4-1BB. In some embodiments, the fusion protein, or one or more components thereof, comprises an agonistic 4-1BB scFv or an agonistic 4-1BB peptide.
[0268] In some embodiments, the immune cell receptor target is CD96. In some embodiments, a component of a fusion protein of the invention may comprise CD96 or a variant thereof. In some embodiments, a component of a fusion protein of the invention may comprise an antagonist or agonist of CD96.
[0269] In some embodiments, a component of a fusion protein of the invention may comprise CD226 or a variant thereof. In some embodiments, a component of a fusion protein of the invention may comprise an antagonist or agonist of CD226.
[0270] In some embodiments, a component of a fusion protein of the invention may comprise TIM-3 or a variant thereof, hi some embodiments, a component of a fusion protein of the invention may comprise an antagonist or agonist of TIM-3.
[0271] In some embodiments, the immune cell receptor target is CD111. In some embodiments, a component of a fusion protein of the invention may comprise CD111 or a variant thereof. In some embodiments, a component of a fusion protein of the invention may comprise an antagonist or agonist of CD111.
[0272] In some embodiments, the immune cell receptor target is CD112. In some embodiments, a component of a fusion protein of the invention may include CD112 or a variant thereof. In some embodiments, a component of a fusion protein of the invention may include an antagonist or agonist of CD112.
[0273] In some embodiments, the immune cell receptor target is CD113. In some embodiments, a component of a fusion protein of the invention may comprise CD113 or a variant thereof. In some embodiments, a component of a fusion protein of the invention may comprise an antagonist or agonist of CD113.
[0274] In some embodiments, the immune cell receptor target is CD115. In some embodiments, a component of a fusion protein of the invention may comprise CD115 or a variant thereof. In some embodiments, a component of a fusion protein of the invention may comprise an antagonist or agonist of CD115.
[0275] In some embodiments, the immune cell receptor target is TIGIT. In some embodiments, a component of the fusion protein of the invention may comprise TIGIT or a variant thereof. In some embodiments, a component of the fusion protein of the invention may comprise an antagonist or agonist of TIGIT.
[0276] In some embodiments, the immune cell receptor target is KIR2DL1, KIR2DL2, or KIR2DL3, or a variant thereof. In some embodiments, a component of a fusion protein of the invention may comprise KIR2DL1, KIR2DL2, or KIR2DL3, or a variant thereof. In some embodiments, a component of a fusion protein of the invention may comprise an antagonist or agonist of KIR2DL1, KIR2DL2, or KIR2DL3.
[0277] In some embodiments, the immune cell receptor target is HLA-C. In some embodiments, a component of the fusion protein of the invention may include an antagonist or agonist of HLA-C. In some embodiments, a component of the fusion protein of the invention may include an antagonist or agonist of HLA-C.
[0278] In some embodiments, the immune cell receptor target is NKG2A (CD94) or a variant thereof. In some embodiments, a component of a fusion protein of the invention may comprise NKG2A (CD94) or a variant thereof. In some embodiments, a component of a fusion protein of the invention may comprise an antagonist or agonist of NKG2A (CD94) or a variant thereof.
[0279] In some embodiments, the immune cell receptor target is HLA-E. In some embodiments, a component of the fusion protein of the invention may include an antagonist or agonist of HLA-E. In some embodiments, a component of the fusion protein of the invention may include an antagonist or agonist of HLA-E.
[0280] In some embodiments, the immune cell receptor target is 2B4 or a variant thereof. In some embodiments, a component of a fusion protein of the invention may comprise 2B4 or a variant thereof. In some embodiments, a component of a fusion protein of the invention may comprise an antagonist or agonist of 2B4 or a variant thereof.
[0281] In some embodiments, the immune cell receptor target is CD48 or a variant thereof. In some embodiments, a component of the fusion protein of the invention may include an antagonist or agonist of CD48. In some embodiments, a component of the fusion protein of the invention may include an antagonist or agonist of CD48 or a variant thereof.
[0282] In some embodiments, the immune cell receptor target is NKG2D or a variant thereof. In some embodiments, a component of a fusion protein of the invention may comprise NKG2D or a variant thereof. In some embodiments, a component of a fusion protein of the invention may comprise an antagonist or agonist of NKG2D or a variant thereof.
[0283] In some embodiments, the immune cell receptor target is MICA / B or ULBP1 or a variant thereof. In some embodiments, a component of the fusion protein of the invention may include an antagonist or agonist of MICA / B or ULBP1. In some embodiments, a component of the fusion protein of the invention may include an antagonist or agonist of MICA / B or ULBP1 or a variant thereof.
[0284] In any one of the above-mentioned embodiments, the immune cell is a NK cell, a T cell, a dendritic cell (DC), an antigen-presenting cell (APC), a macrophage, or a tumor-associated macrophage (M1).
[0285] Immune Cell Receptors or Ligands In some embodiments, the fusion protein or one or more components thereof bind to an immune cell receptor or ligand. In some embodiments, binding to an immune cell receptor or ligand results in activation of NK cells (cytokine (IFNγ and TNF) production, antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP)). In some embodiments, the receptor is an Fc receptor. In some embodiments, binding to an Fc receptor results in activation of NK cells (ADCC and ADCP). In some embodiments, the Fc receptor is an Fc receptor. γReceptor, Fc ε Receptor, Fc α Receptor, Fc μ Receptor, or Fc δ In some embodiments, the immune cell receptor or ligand is a TNF superfamily member or receptor thereof, a TNF-L superfamily member or receptor thereof, transferrin or receptor thereof, human serum albumin or receptor thereof, or a lipocalin structural family member or receptor thereof.
[0286] Linker In some embodiments, the components of the fusion protein of the invention may be optionally connected via a peptide linker. The residues of the linker may be selected from natural amino acids, unnatural amino acids, and modified amino acids. Typically, the linker connects the carboxy terminus of the first component to the amino terminus of the second component. The linker may alter the distance between the two structural components of the fusion protein and may also alter the flexibility of this region. The linker may comprise any number of amino acids. Thus, a linker may comprise, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60 or more amino acids. In some embodiments, the linker may be comprised of 3 to 60 amino acid residues, 3 to 40 amino acid residues, 3 to 30 amino acid residues, 3 to 24 amino acid residues, 3 to 18 amino acid residues, or 3 to 15 amino acid residues. The linker may, for example, comprise a repeating subsequence of 2, 3, 4, 5, or more amino acid residues, and may comprise 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or more units of this repeating subsequence.
[0287] The linker may be a natural or designed sequence. Useful peptide linkers in the fusion proteins of the invention include, but are not limited to, glycine linkers, glycine-rich linkers, serine-glycine linkers, and the like. A glycine-rich linker contains at least about 50% glycine, preferably at least about 60% glycine. In one embodiment, the linker contains the amino acid sequence Gly-Ser or repeats thereof. See, e.g., Huston et al., Methods in Enzymology 203:46-88 (1991). In another embodiment, the linker contains the amino acid sequence Gly-Lys or repeats thereof. See, e.g., Whitlow et al., Protein Eng. 6:989 (1993). In another embodiment, the linker contains the amino acid sequence Gly-Gly-Ser or repeats thereof. In another embodiment, the linker comprises the amino acid sequence Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 29) or repeats thereof. In a particular embodiment, the linker comprises the amino acid sequence Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 30). In a particular embodiment, the linker comprises Gly-Gly-Ser or Gly-Gly-Gly-Ser or repeats of 2 to 12 units of Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 29). See US Pat. No. 6,541,219 for examples of peptide linkers. In one embodiment, the linker may comprise the sequence GDPLVTAASVLEFGGSGGGSEGGGSEGGGSEGGGSDI (SEQ ID NO: 31).
[0288] Linkers are useful for separating the two components of a fusion protein, which allows the components to fold correctly, reduces potential steric hindrance, and / or contributes to optimal receptor binding. Those skilled in the art are familiar with the design and selection of peptide linkers. See, for example, Robison et al., 1998, Proc. Natl. Acad. Sci. USA 95:5929-5934. Automated programs are also available for the design of peptide linkers (e.g., Crasto et al., 2000, Protein Engineering 13:309-312).
[0289] Optional Other Elements The fusion protein may optionally further comprise elements different from component A, component B, component C, and / or component D. Such additional elements may include, but are not limited to, an initiation methionine, a signal peptide, an antigenic polypeptide, a trimerization domain, a higher order multimerization domain, and a purification tag such as His-6. An exemplary purification tag is ASHHHHHHM (SEQ ID NO: 46). In one embodiment, the fusion protein of the invention optionally comprises a trimerization domain.
[0290] The fusion proteins of the present invention optionally include a signal peptide. The signal peptide can vary depending on the needs of the user, the expression system, and other factors, as will be appreciated by those of skill in the art. Signal peptides are well known in the art, and any desired signal peptide can be used, including signal peptides recognized / predicted by publicly available signal peptide recognition software known to those of skill in the art.
[0291] In some embodiments, the fusion proteins of the invention include a hinge region that provides flexibility between the components. See Lobner et al. (2016) Immunol. Reviews 270:113-131. In some embodiments, component Y and component Z2 are connected via a hinge (e.g., an IgG hinge). In some embodiments, component Z1' and component Z2' are connected via a hinge (e.g., an IgG hinge).
[0292] In some embodiments, the N-linked glycan is attached to Asn on component A and / or component B. In some embodiments, the N-linked glycan is attached to Asn297 on component A and / or component B. Without wishing to be bound by theory, this may facilitate FcR binding and increase the structural integrity and thermal stability of the fusion protein. See Arnold et al. (2007) Annu Rev Immunol 25:21-50.
[0293] In some embodiments, component A and / or component B comprises a K to A mutation. In some embodiments, component A and / or component B comprises a K322A mutation. Without wishing to be bound by theory, this may reduce C1q binding and complement mediated lysis. See Idusogie et al. (2000) J. Immunol 164:4178-4184.
[0294] In some embodiments, component A and component B contain knob-into-hole mutations. In some embodiments, component A contains the mutation Y349C and the mutation T366W, and component B contains the mutation D356C, the mutation T366S, the mutation L368A, and the mutation Y407V ("knobs-into-hole" mutations). Without wishing to be bound by theory, this may promote heterodimerization over homodimerization. See Merchant et al. (1998) Nature Biotech. 16:677-681.
[0295] In some embodiments, component A and / or component B comprise a mutation that increases binding to the neonatal Fc receptor (FcRn). In some embodiments, component A and / or component B comprise the mutation M428L and the mutation N434S. Without wishing to be bound by theory, this may increase binding to the neonatal Fc receptor (FcRn) on various cells and increase serum half-life. See Kuo and Aveson, (2011), mAbs 3:422-430.
[0296] Trimerization domain Trimerization domains are well known in the art. Non-limiting examples of trimerization domains suitable as heterologous trimerization domains in the fusion proteins of the invention include the GCN4 leucine zipper (Harbury et al., 1993, "A switch between two-, three-, and four-stranded coiled coils in GCN4 leucine zipper mutants", Science 262(5138):1401-7), a 35 amino acid sequence from a pulmonary surfactant protein (Hoppe et al., 1994, "A parallel three stranded alpha helical bundle at the nucleation site of collagen triple-helix formation", FEBS letters 344(2-3):191-5), a short repeated heptad sequence from collagen (McAlinden et al., 2003, "Alpha-helical coiled-coil oligomerization domains are almost ubiquitous in the collagen superfamily", J Biol 1999, 11, 142-143), a 35 amino acid sequence from a pulmonary surfactant protein (Hoppe et al., 1994, "A parallel three stranded alpha helical bundle at the nucleation site of collagen triple-helix formation", FEBS letters 344(2-3):191-5), a 35 amino acid sequence from a collagen-derived short repeated heptad sequence ... Chem. 278(43):42200-7, published epub Aug. 14, 2003), and the bacteriophage T4 fibritin "foldon" (see, e.g., Miroshnikov et al., 1998, "Engineering trimeric fibrous proteins based on bacteriophage T4 adhesins," Protein Eng. 11(4):329-32). Exemplary trimerization domains are also disclosed in U.S. Pat. Nos. 6,911,205 and 8,147,843 and U.S. Patent Publication No. 2010 / 0136032. An exemplary trimerization sequence is the T4 "foldon" having the sequence GYIPEAPRDGQAYVRKRGEWVLLSTFL (SEQ ID NO:47). Another exemplary trimerization domain is derived from thrombospondin-1 and has the sequence VTTLQDSIRKVTEENKELANELRR (SEQ ID NO:56).
[0297] qualification The present invention encompasses variants of the fusion proteins described herein. It is generally desirable for the variants to exhibit enhanced binding ability to a given molecule, but in some embodiments, variants may be designed that have slightly reduced activity compared to other fusion proteins of the present invention, for example where reduced activity is deliberately desired. In addition, variants or derivatives may be generated that have altered multimerization properties.
[0298] Desirably, variants or derivatives of the fusion proteins of the invention maintain the hydrophobicity / hydrophilicity of the amino acid sequence.
[0299] In additional embodiments, the fusion proteins of the invention are variants and / or derivatives of the amino acid sequences shown in SEQ ID NOs: 14, 15, 16, 17, 18, 19, 20, 21, 22, 32, 33, 34, 35, 49, 50, 51, 52, 53, 54, 55, 65, 66, 67, 68, 69, 70, or 71. In one embodiment, the variants of the fusion proteins of the invention have at least 80% or more sequence identity or homology as understood in the art to SEQ ID NOs: 14, 15, 16, 17, 18, 19, 20, 21, 22, 32, 33, 34, 35, 49, 50, 51, 52, 53, 54, 55, 65, 66, 67, 68, 69, 70, or 71, and more preferably ... 14, 15, 16, 17, 18, 19, 20, 21, 22, 32, 33, 34, 35, 49, 50, 51, 52, 53, 54, 55, 65, 66, 67, 68, 69, 70, or 71.
[0300] The present invention also provides for chemical modifications of the fusion proteins of the invention. Non-limiting examples of such modifications may include, but are not limited to, aliphatic esters or amides of the carboxyl terminus or carboxyl side chain-containing residues, O-acyl derivatives of hydroxyl group-containing residues, and N-acyl derivatives of amino terminal amino acids or amino group-containing residues, such as lysine or arginine.
[0301] Other derivatives of the fusion proteins of the invention include incorporated unnatural amino acid residues or phosphorylated amino acid residues, such as phosphotyrosine, phosphoserine, or phosphothreonine residues. Other potential modifications include sulfonation, biotinylation, or the addition of other moieties, particularly those that have a molecular shape similar to a phosphate group.
[0302] Derivatives also include polypeptides modified by glycosylation. These derivatives can be made by altering the glycosylation pattern during synthesis and processing in various alternative eukaryotic host expression systems, or during other processing steps. Methods for effecting glycosylation modifications include exposing the fusion protein to glycosylating enzymes, e.g., mammalian glycosylating enzymes, from the cells that normally perform such processing. Alternatively, deglycosylating enzymes can be used to remove carbohydrates attached during production in eukaryotic expression systems. Coding sequences can also be modified to add glycosylation sites or to delete or disable glycosylation sites. Additionally, the proteins can be produced in prokaryotic host expression systems in cases where glycosylation is undesirable.
[0303] Mutants and / or derivatives of the fusion proteins of the invention can be prepared by chemical synthesis, or by using site-directed mutagenesis (Gillman et al., Gene 8:81 (1979); Roberts et al., Nature 328:731 (1987); or Innis, ed., 1990, PCR Protocols: A Guide to Methods and Applications, Academic Press, New York, NY) or the polymerase chain reaction (PCR; Saiki et al., Science 239:487 (1988)) to modify the nucleic acid encoding the complete receptor.
[0304] In additional embodiments, the fusion proteins of the invention may further comprise one or more additional polypeptide domains added to facilitate protein purification, to increase recombinant protein expression, or to increase recombinant protein solubility. Such purification / expression / solubility enhancing domains include, but are not limited to, metal chelating peptides such as histidine-tryptophan modules that allow purification on immobilized metals (Porath, 1992, Protein Expr Purif 3:263-281), Protein A domains that allow purification on immobilized immunoglobulins, and domains utilized in the FLAGS extension / affinity purification system (Immunex, Seattle, WA). Inclusion of a cleavable linker sequence, such as Factor Xa or enterokinase (Invitrogen, San Diego, CA) between the purification domain and the fusion of components A and B is useful to facilitate purification.
[0305] Fusion expression vectors include pGEX (Pharmacia, Piscataway, NJ), pMAL (New England Biolabs, Beverly, MA), and pRITS (Pharmacia, Piscataway, NJ), which fuse glutathione S-transferase (GST), maltose B-binding protein, or protein A, respectively, to the target recombinant protein. EBV, BKV, and other episomal expression vectors (Invitrogen) can also be used. Retroviral and lentiviral expression vectors can also be used. In addition, any one of a number of in vivo expression systems designed for high-level expression of recombinant proteins in organisms can be used to produce the fusion proteins set forth herein.
[0306] As discussed above, the fusion protein of the invention may contain a heterologous signal sequence at its N-terminus. In certain host cells (e.g., mammalian host cells), expression and / or secretion of the fusion protein may be increased by the use of a heterologous signal sequence. Signal sequences are typically characterized by a core of hydrophobic amino acids that are generally cleaved from the mature protein during secretion in one or more cleavage events. Such signal peptides contain processing sites that allow the signal sequence to be cleaved from the mature protein as the mature protein passes through the secretory pathway. Thus, the invention relates to polypeptides having a signal sequence as well as polypeptides from which the signal sequence has been proteolytically cleaved (i.e., cleavage products).
[0307] To enhance stability and / or reactivity, the fusion proteins of the invention may be modified to incorporate one or more polymorphisms in the amino acid sequence that arise from natural allelic variation. It is also possible to substitute or add D-amino acids, non-natural amino acids, or non-amino acid analogs to create modified fusion proteins within the scope of the invention.
[0308] The amino acid sequences of the invention may be produced by expression of a nucleotide sequence encoding the amino acid sequence in an appropriate expression system.
[0309] Additionally or alternatively, the fusion protein itself can be made in whole or in part using chemical methods to synthesize the desired amino acid sequence. For example, the polypeptide can be synthesized by solid phase techniques, cleaved from the resin, and purified by preparative high performance liquid chromatography (e.g., Creighton, (1983), Proteins: Structures And Molecular Principles, WH Freeman and Co, New York, NY). The composition of the synthetic polypeptide can be confirmed by amino acid analysis or sequencing (e.g., Edman degradation). The amino acid sequence of the fusion protein of the invention, or any portion thereof, can also be directly modified during synthesis and / or combined with other subunit sequences, or any portion thereof, using chemical methods to generate mutant polypeptides.
[0310] Assays for measuring the biological activity of any homologues, derivatives, or variants of any of the fusion proteins of the present invention are well known in the art.
[0311] Activity and usefulness In one embodiment, the fusion proteins of the invention effectively immobilize tumor cells, inhibiting or preventing the cells from migrating, invading neighboring tissues, and / or metastasizing to distant sites. In another embodiment, the fusion proteins of the invention inhibit or prevent tumor cells from escaping phagocytosis by phagocytes such as macrophages, while promoting apoptosis and / or immune destruction of the tumor cells. In other embodiments, the fusion proteins of the invention inhibit or prevent tumor cells from escaping phagocytosis by phagocytes, while promoting apoptosis of neighboring tumor cells. Thus, the fusion proteins of the invention promote tumor cell destruction by any one of a number of mechanisms.
[0312] Ligands or receptors for PD-1 are expressed on a wide variety of tumor cells, including solid tumor cells. Thus, in one embodiment, the invention provides a method of treating a proliferative disorder by administering to a subject diagnosed with the disorder a therapeutically effective amount of a fusion protein of the invention.
[0313] The fusion proteins of the invention can be administered to individuals (e.g., mammals, including animals and humans) suffering from cell proliferative disorders such as cancer, as well as malignant and benign tumors. In certain embodiments of the invention, the individual receiving treatment is a human.
[0314] The fusion proteins are believed to be effective against a wide range of tumor types, including, but not limited to, ovarian, cervical, breast, prostate, testicular, lung, kidney, colon, skin, brain cancer, and leukemias, including acute myeloid leukemia, chronic myeloid leukemia, acute lymphocytic leukemia, and chronic lymphocytic leukemia.
[0315] More specifically, cancers that may be treated by the compounds, compositions, and methods of the invention include, but are not limited to, the following cancers: Sarcomas, such as angiosarcoma, fibrosarcoma, rhabdomyosarcoma, and liposarcoma, myxoma, rhabdomyoma, fibroma, lipoma, and cardia cancer, including teratoma, etc. Lung cancer, including squamous cell carcinoma, undifferentiated small cell carcinoma, undifferentiated large cell carcinoma, and bronchogenic carcinoma such as adenocarcinoma, bronchioloalveolar carcinoma, bronchial adenoma, sarcoma, lymphoma, chondroitin hamartoma, and mesothelioma, etc. gastrointestinal cancers, including esophageal cancers such as squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, and lymphoma; gastric cancers such as carcinoma, lymphoma, and leiomyosarcoma; pancreatic cancers such as pancreatic ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumor, and vipoma; small intestine cancers such as adenocarcinoma, lymphoma, carcinoid tumor, Kaposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, and fibroma; and colon cancers such as adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, and leiomyoma; Cancers of the urinary tract, including kidney cancer such as adenocarcinoma, Wilms' tumor (nephroblastoma), lymphoma, and leukemia; cancers of the bladder and urinary tract, including squamous cell carcinoma, transitional cell carcinoma, and adenocarcinoma; cancers of the prostate, including adenocarcinoma and sarcoma; and cancers of the genitourinary tract, including testicular cancer, including seminoma, teratoma, embryonal carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, stromal cell carcinoma, fibroma, fibroadenoma, adenoid tumor, and lipoma; Liver cancer, including hepatocellular carcinoma such as primary hepatocellular carcinoma, cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, and hemangioma, etc. Bone cancer, including osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticulum cell sarcoma), multiple myeloma, malignant giant cell chondroma, osteochondroma (osteochondroid exostosis), benign chondroma, chondroblastoma, chondromyxoid fibroma, osteoid osteoma, and giant cell tumor; Cancers of the nervous system, including skull cancers such as osteoma, hemangioma, granuloma, xanthomas, and osteitis deformans; meningeal cancers such as meningioma, meningeal sarcoma, and gliomatosis; brain cancers such as astrocytoma, medulloblastoma, glioma, ependymoma, germinoma (pineal tumor), glioblastoma multiforme, oligodendroglioma, schwannoma, retinoblastoma, and congenital tumors; and spinal cancers such as neurofibroma, meningioma, glioma, and sarcoma. uterine cancer, such as endometrial cancer; cervical cancer, such as cervical carcinoma and precancerous cervical dysplasia; ovarian cancer, such as serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma, granulosa theca cell tumor, Sertoli-Leydig cell tumor, dysgerminoma, and ovarian carcinoma, including malignant teratoma; vulvar cancer, such as squamous cell carcinoma, carcinoma in situ, adenocarcinoma, fibrosarcoma, and melanoma; vaginal cancer, such as clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma, and embryonal rhabdomyosarcoma; and gynecological cancer, including fallopian tube cancer, such as carcinoma; Acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, myeloproliferative disorders, multiple myeloma, and myelodysplastic syndromes, Hodgkin's lymphoma, non-Hodgkin's lymphoma (malignant lymphoma), and Waldenstrom's macroglobulinemia, angioimmunoblastic T-cell lymphoma (AITL), chronic lymphocytic leukemia (CLL), acute nonlymphocytic leukemia, chronic lymphocytic leukemia, acute granulocytic leukemia, chronic granulocytic leukemia, monocytic leukemia, myeloblastic leukemia, myelocytic leukemia, myelomonocytic leukemia, Naegeli leukemia, plasma cell leukemia, plasma cell leukemia, promyelocytic leukemia, Reeder cell leukemia, cylindrical ... blood cancers, including blood cancers such as leukemia, stem cell leukemia, subleukemic leukemia, acute promyelocytic leukemia, adult T-cell leukemia, aleukemic leukemia, aleukocytic leukemia, basophilic leukemia, blast cell leukemia, bovine leukemia, chronic myelocytic leukemia, leukemia cutis, fetal cell leukemia, anaplastic cell leukemia, eosinophilic leukemia, gross leukemia, hairy cell leukemia, hemoblastic leukemia, hemoblastic leukemia, histiocytic leukemia, stem cell leukemia, acute monocytic leukemia, leukopenic leukemia, lymphocytic leukemia, lymphoblastic leukemia, lymphocytic leukemia, lymphosarcoma cell leukemia, mast cell leukemia, megakaryocytic leukemia, and small myeloblastic leukemia; Skin cancer, including malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, atypical nevi, lipoma, hemangioma, dermatofibroma, keloids, and psoriasis; Adrenal cancer, including neuroblastoma.
[0316] More specific examples of such cancers include kidney cancer, breast cancer, colon cancer, rectal cancer, colorectal cancer, lung cancer, including small cell lung cancer, non-small cell lung cancer, lung adenocarcinoma, and lung squamous cell carcinoma; squamous cell carcinoma (e.g., squamous cell carcinoma), cervical cancer, ovarian cancer, prostate cancer, liver cancer, bladder cancer, peritoneal cancer, hepatocellular carcinoma, gastric cancer, including gastrointestinal cancer, gastrointestinal stromal tumor (GIST), pancreatic cancer, head and neck cancer, glioblastoma, Hematological malignancies including retinoblastoma, astrocytoma, theca cell tumor, androgenitoma, liver cancer, non-Hodgkin's lymphoma (NHL), multiple myeloma, and acute hematological malignancies; endometrial or uterine cancer, endometriosis, fibrosarcoma, choriocarcinoma, salivary gland carcinoma, vulvar cancer, thyroid cancer, esophageal cancer, liver cancer, anal cancer, penile cancer, nasopharyngeal cancer, laryngeal cancer, Kaposi's sarcoma, melanoma, skin cancer, Schwannoma, oligodendroglioma sarcoma, neuroblastoma, rhabdomyosarcoma, osteogenic sarcoma, leiomyosarcoma, urinary tract cancer, thyroid cancer, Wilms' tumor, and B-cell lymphomas (low-grade / follicular non-Hodgkin's lymphoma (NHL), small lymphocytic (SL) NHL; intermediate-grade / follicular NHL; intermediate-grade diffuse NHL; high-grade immunoblastic NHL; high-grade lymphoblastic NHL; high-grade small non-cleaved cell NHL; bulky mass disease NHL; mantle cell lymphoma) and Waldenstrom's macroglobulinemia), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), hairy cell leukemia, chronic myeloblastic leukemia, and post-transplant lymphoproliferative disorder (PTLD), as well as abnormal blood vessel proliferation associated with nevus syndrome, edema (such as that associated with brain tumors), and Meigs' syndrome. As used herein, "tumor" refers to all neoplastic cell growth and proliferation, whether malignant or benign, and all pre-cancerous and cancerous cells and tissues.
[0317] Cancer may be a solid tumor, which may or may not be metastatic. Cancer may also occur in disorganized tissue, as in the case of leukemia. Thus, as presented herein, the term "tumor cell" includes cells that are affected by any one of the above-mentioned disorders.
[0318] In a preferred embodiment, the cancer is a solid tumor. In a preferred embodiment, the cancer is one of pancreatic cancer, breast cancer, ovarian cancer, bladder cancer, melanoma, and glioblastoma.
[0319] In another embodiment, the cancer is a hematological cancer. In a preferred embodiment, the hematological cancer is one of acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).
[0320] Pharmaceutical Compositions and Methods of Administration Typically, administration of the compositions of the invention is parenteral, by subcutaneous, intravenous, intramuscular, or intraperitoneal injection, or by infusion or any other acceptable systemic administration method. In a preferred embodiment, administration is by subcutaneous injection. In another preferred embodiment, administration is by intravenous infusion, which may typically occur over a period of about 1-5 hours. Additionally, there are a variety of oral delivery methods for administration of therapeutic proteins, which are applicable to the therapeutic fusion proteins of the invention.
[0321] To optimize safety and efficacy, therapeutic doses are often titrated from low to high levels. Daily doses generally fall within the range of about 0.01-20 mg protein per kilogram of body weight. Dosage ranges are typically about 0.1-5 mg protein per kilogram of body weight. Various modifications or derivatives of the fusion protein may be made, such as the addition of polyethylene glycol chains (PEGylation), to affect the pharmacokinetic and / or pharmacodynamic properties of the fusion protein.
[0322] To administer fusion proteins by methods other than parenteral administration, it may be necessary to coat the protein with or co-administer the protein with a material that prevents inactivation of the protein. For example, the protein may be administered in incomplete adjuvant, co-administered with enzyme inhibitors, or administered in liposomes. Enzyme inhibitors include pancreatic trypsin inhibitor, diisopropylfluorophosphate (DEP), and trasylol. Liposomes include water-in-oil-in-water CGF emulsions as well as conventional liposomes (Strejan et al., 1984, J. Neuroimmunol. 7:27).
[0323] The compositions of the present invention can be administered in the form of a simple solution, but more typically are combined with other substances, such as carriers, preferably pharma- ceutically acceptable carriers. Useful pharma-ceutically acceptable carriers can be any compatible non-toxic substance suitable for delivering the compositions of the present invention to a patient. Carriers include sterile water, alcohol, fats, waxes, and inert solids. Pharmaceutically acceptable adjuvants (buffers, dispersants) may be incorporated into the pharmaceutical composition. In general, compositions useful for parenteral administration of such drugs are well known, for example, Remington's Pharmaceutical Science, 17th Edition (Mack Publishing Co., Easton, Pa., 1990). Alternatively, the compositions of the present invention may be introduced into the patient's body by an implantable drug delivery system (Urquhart et al., 1984, Ann. Rev. Pharmacol. Toxicol., vol. 24:199).
[0324] Therapeutic formulations may be administered in many conventional dosage forms. Typically, the formulation comprises at least one active ingredient together with one or more pharma- ceutically acceptable carriers. The formulation may include those suitable for oral, rectal, nasal, or parenteral administration (including subcutaneous, intramuscular, intravenous, and intradermal administration).
[0325] The formulations may conveniently be provided in unit dosage form and may be prepared by any method well known in the art of pharmacy. See, for example, Gilman et al., eds. (1990), The Pharmacological Bases of Therapeutics, 8th ed., Pergamon Press, and Remington's Pharmaceutical Sciences, supra, Easton, Pa.; Avis et al., eds. (1993), Pharmaceutical Dosage Forms: Parenteral Medications, Dekker, New York; Lieberman et al., eds. (1990), Pharmaceutical Dosage Forms: Tablets, Dekker, New York, and Lieberman et al., eds. (1990), Pharmaceutical Dosage Forms: Disperse Systems, Dekker, New York.
[0326] In additional embodiments, the present invention contemplates administering a fusion protein by gene therapy, e.g., administering an isolated nucleic acid encoding a fusion protein of interest. The protein building blocks of the fusion proteins of the present invention (e.g., component A and component B) have been characterized both in terms of the nucleic acid sequence encoding the protein and in terms of the amino acid sequence of the protein that results from them. Manipulation of such isolated nucleic acids by recombinant DNA techniques is well within the capabilities of one of skill in the art. Codon optimization aimed at maximizing recombinant protein yield in a particular cell background is also well within the capabilities of one of skill in the art. Administration of an isolated nucleic acid encoding a fusion protein is encompassed by the expression "administration of a therapeutically effective amount of a fusion protein of the present invention." Gene therapy methods are well known in the art. See, for example, WO 96 / 07321, which discloses the use of gene therapy methods to generate intracellular antibodies. Gene therapy methods have also been successfully demonstrated in human patients. See, e.g., Baumgartner et al., 1998, Circulation 97:12, 1114-1123, and more recently, Fatham, 2007, "A gene therapy approach to treatment of autoimmune diseases", Immun. Res. 18:15-26, and U.S. Patent No. 7,378,089, both of which are incorporated herein by reference. See also, Bainbridge et al., 2008, "Effect of gene therapy on visual function in Leber's congenital Amaurosis", N Engl Med 358:2231-2239, and Maguire et al., 2008, "Safety and efficacy of gene transfer for Leber's congenital Amaurosis", N Engl J Med 358:2240-8. There are two major methods for introducing nucleic acid (optionally contained within a vector) encoding a fusion protein into a patient's cells in vivo and ex vivo.For in vivo delivery, the nucleic acid is injected directly into the patient, usually at the site where the fusion protein is required. For ex vivo treatment, patient cells are removed, the nucleic acid is introduced into these isolated cells, and the modified cells are administered to the patient either directly or encapsulated in a porous membrane that is implanted into the patient (see, for example, U.S. Pat. Nos. 4,892,538 and 5,283,187). There are various techniques available for introducing nucleic acids into living cells. The techniques vary depending on whether the nucleic acid is introduced into cultured cells in vitro or into the cells of the intended host in vivo. Suitable techniques for introducing nucleic acids into mammalian cells in vitro include the use of liposomes, electroporation, microinjection, cell fusion, DEAE dextran, calcium phosphate precipitation, etc. Vectors commonly used for ex vivo gene delivery are retroviral and lentiviral vectors.
[0327] Preferred in vivo nucleic acid transfer methods include transfection using viral vectors such as adenovirus, herpes simplex type I virus, adeno-associated virus, lipid-based systems (useful lipids for lipid-mediated transfer of the above genes include DOTMA, DOPE, and DC-Chol), naked DNA, and transposon-based expression systems. For a review of currently known gene marking and gene therapy protocols, see Anderson et al., Science 256:808-813 (1992). See also WO 93 / 25673 and the references cited therein.
[0328] "Gene therapy" includes both conventional gene therapy, in which a long-term effect is achieved with a single treatment, and the administration of gene therapy drugs, which involve single or repeated administration of therapeutically effective DNA or mRNA. To improve uptake of oligonucleotides, the oligonucleotides may be modified, for example, by replacing their negatively charged phosphodiester groups with uncharged groups. The fusion proteins of the invention can be delivered locally, for example, to a tumor bed, intrathecally, or systemically using gene therapy (e.g., by vectors that selectively target a particular tissue type, such as tissue-specific adeno-associated viral vectors). In some embodiments, a gene encoding any of the fusion proteins of the invention may be transfected ex vivo into primary cells (such as lymphocytes or stem cells) derived from an individual, and then the transfected cells may be returned to the individual's body.
[0329] "Treating" or "treatment" refers to a treatment aimed at preventing or slowing (alleviating) a targeted pathological condition or disorder. A subject is successfully "treated" if, after receiving a therapeutic amount of a fusion protein of the invention according to the methods of the invention, the subject shows an observable and / or measurable reduction or loss of one or more signs and symptoms of the particular disease. For example, for cancer, a subject is successfully "treated" if the number of cancer cells is reduced or lost, tumor size is reduced, tumor metastasis is inhibited (i.e., delayed to some extent and preferably stopped), tumor growth is inhibited to some extent, remission time is extended, and / or one or more symptoms associated with the particular cancer are alleviated to some extent, morbidity and mortality are reduced, and quality of life issues are improved. The patient may also experience a reduction in signs or symptoms of the disease. A complete response, defined as the disappearance of all signs of cancer, or a partial response, where the tumor size is reduced, preferably by more than 50%, more preferably by up to 75%, may be achieved by treatment. A patient is also considered to be treated if they experience stable disease. These parameters for assessing successful treatment and improvement of disease can be readily measured by routine methods well known to physicians of ordinary skill in the art.
[0330] In the context of treating cancer, the fusion proteins of the invention may optionally be administered to the patient in combination with other chemotherapeutic agents. Suitable chemotherapeutic agents include, for example, alkylating agents such as thiotepa and cyclophosphamide (Cytoxan™), alkylsulfones such as busulfan, improsiilfan, and piposulfan, aziridines such as benzodopa, carboquone, meturedopa, and uredopa, altretamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide, and trimethylolmelamine (TMP), and the like. Ethyleneimines and methylamelamines, including trimethylolomelamine, chlorambucil, chlornaphazine, cholophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichiin, phenesterine, prednimustine, trophosphamide, and nitrogen mustards, such as uracil mustard, carbapenem, carbamazepine ... Nitrosoureas such as sucrine, chlorozotocin, fotemustine, lomustine, nimustine, and ranimustine, aclacinomycin, actinomycin, autramycin, azaserine, bleomycin, cactinomycin, calicheamicin, carabicin, caminomycin, carzinophilin, chromomycin, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin, epirubicin, esorubicin, idarubicin, marcetine, Antibiotics such as thromycin, mitomycin, mycophenolic acid, nogalamycin, olivomycin, peplomycin, potfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, and zorubicin; antimetabolites such as methotrexate and 5-fluorouracil (5-FU); denopterin, methotrexate, pteropterin;folic acid analogues such as bromoglutamine, bromoglutamine, and trimetrexate; purine analogues such as fludarabine, 6-mercaptopurine, thiamiprine, and thioguanine; pyrimidine analogues such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine, and 5-FU; androgens such as calsterone, dromostanolone propionate, epithiostanol, mepitiostane, and testolactone; antiadrenal agents such as aminoglutethimide, mitotane, and trilostane; Any folic acid supplement, aceglatone, aldophosphamide glycoside, aminolevulinic acid, amsacrine, bestravcil, bisantrene, edatraxate, defofamine, demecolcine, diazicon, elformithine, elliptinium acetate, etoglucide, gallium nitrate, hydroxyurea, lentinan, lonidamine, mitoguazone, mitoxantrone, mopidamol, nitracrine, pentostatin, phenameth, pirarubicin, podophyllinic acid, 2-ethyl hydroxylase Razid, procarbazine, PSK®, razoxane, sizofiran, spirogermanium, tenuazonic acid, triaziquone, 2,2',2"-trichlorotriethylamine, urethane, vindesine, dacarbazine, mannomustine, mitobronitol, mitolactol, pipobroman, gacytosine, arabinoside ("Ara-C"), cyclophosphamide, thiotepa, paclitaxel (TAXOL®, Bristol-Myers Squibb Oncology, Princeton, NJ), and docetaxel (TAXOTERE®). Taxanes such as cyclosporine, ...Difluoromethylornithine (DMFO), retinoic acid, esperamicin, capecitabine, and pharma- ceutically acceptable salts, acids, or derivatives of any of the above chemotherapeutic agents.
[0331] Other chemotherapeutic agents further include anti-hormonal agents that act to regulate or inhibit the action of hormones on tumors, such as anti-estrogens including tamoxifen, raloxifene, aromatase-inhibiting 4(5)-imidazole, 4-hydroxytamoxifen, trioxyphene, ketoxifene, LY117018, onapristone, and toremifene (Fareston), and anti-androgens such as flutamide, nilutamide, bicalutamide, leuprolide, and goserelin, and pharmaceutically acceptable salts, acids, or derivatives of any of the above anti-hormonal agents.
[0332] Other tumor cytotoxic agents that can be used in combination with the fusion proteins of the present invention are themselves fusion proteins. Examples of tumor cytotoxic fusion proteins are CTLA-4-FasL and Fn14-TRAIL, which can act as cis-loop-back proteins by forming an auto-apoptotic signaling loop on the surface of tumor cells. See U.S. Patent Nos. 7,569,663, 8,329,657, and 8,039,437, each of which is incorporated by reference in its entirety. These cis-loop-back proteins incorporating TRAIL components can then be administered in combination with chemotherapeutic agents that can sensitize tumor cells to TRAIL and overcome TRAIL resistance, such as proteasome inhibitors and histone deacetylase (HDAC) inhibitors, cycloheximide, imatinib mesylate and other protein tyrosine kinase inhibitors, 17-allylamino-17-demethoxygeldanamycin, arsenic trioxide, and X-linked inhibitor of apoptosis protein small molecule antagonists, and pharmacologic acceptable salts, acids, or derivatives of any of these chemotherapeutic agents.
[0333] Additional information regarding methods of cancer treatment is provided in U.S. Pat. No. 7,285,522, which is incorporated by reference in its entirety.
[0334] The following non-limiting examples illustrate the practice of the present invention. The present invention should not be construed as being limited solely to the compositions and methods described herein, but should be construed to include other compositions and methods as well. Those skilled in the art will appreciate that other compositions and methods are available for carrying out the procedures described herein.
[0335] The practice of the present invention will employ, unless otherwise indicated, conventional techniques of bacterial biology (including recombinant techniques), microbiology, cell biology, biochemistry, and immunology, which are well within the skill of the art. Such techniques are fully described in such publications as "Molecular Cloning: A Laboratory Manual", 4th edition, (Sambrook, ed., 2012), "Oligonucleotide Synthesis", (Gait, 1984), "Culture of Animal Cells", (Freshney, 2010), "Methods in Enzymology", "Handbook of Experimental Immunology", (Weir, 1997), "Gene Transfer Vectors for Mammalian cells", (Miller and Calos, 1987), "Short Protocols in Molecular Biology", (Ausubel, 2002), "Polymerase Chain Reaction: Principles, Applications and Troubleshooting", (Babar, 2011), "Current Protocols in Immunology", (Coligan, 2002), etc. These techniques are applicable to the production of the polynucleotides and polypeptides of the present invention and may therefore be considered in the practice of the present invention. Techniques that are particularly useful for particular embodiments are discussed in the following sections. EXAMPLES
[0336] The present invention will be described in more detail with reference to the following examples. These examples are presented for illustrative purposes only and are not intended to be limiting unless otherwise specified. Therefore, the present invention should not be construed as being limited to the following examples in any way, but rather as embracing any and all variations that become evident as a result of the teachings presented herein.
[0337] Without further description, it is believed that one of ordinary skill in the art can, using the preceding description and the following illustrative examples, make and utilize the compounds of the present invention and practice the claimed methods. Accordingly, the following examples specifically point out preferred embodiments of the present invention, and are not to be construed as limiting the remainder of the disclosure in any way.
[0338] Example 1: Binding of fusion proteins Fusion protein constructs and expression Expression plasmid constructs for these fusion proteins were generated using de novo synthesized gene fragments (Thermo Fisher Scientific) for each of the desired ligand / receptor components linked to synthetic gene fragments for the hinge, CH2, and CH3 domains (i.e., Z2, Z3, Z2', or Z3') of either the A or B chain. Individual components were spliced together by polymerase chain reaction (PCR) using primers containing restriction sites at their ends for cloning into the pCEP4 expression plasmid, an EBV episomal expression vector (originally developed in the Cicchinski laboratory) that replicates extrachromosomally at high copy number. During gene synthesis, the DNA fragments were codon-optimized for expression in Chinese hamster ovary suspension (CHO-S) cells. Fusion proteins were produced by transient co-transfection of A- and B-chain constructs into ExpiCHO-S shake flask cultures using TransIT-Pro reagent (MIRUS) at 37°C for 24 hours, followed by incubation of these cultures at 32°C for a total of 8-10 days. Proteins were purified from the conditioned culture supernatants by mixing with protein A agarose resin overnight at 6°C, followed by harvesting and elution using non-denaturing neutral pH elution buffer (PIERCE). Each fusion protein was verified for size and quality by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE).
[0339] Fusion protein binding assay Ligand constructs expressing full-length cDNAs for human CD155, immunoglobulin domain-ITIM domain-containing T cell immunoreceptor (TIGIT), CD112, and CD16 (FcγRIIIa) were generated by PCR and cloned into pcDNA3.1+ (Thermo Fisher Scientific) expression plasmids. Each expression construct was transfected into CHO-S cells using Lipofectamine 3000 (Thermo Fisher), and stable transfectants were selected by adding G418. Ligand expression was determined by flow cytometry after immunostaining using the appropriate fluorochrome-conjugated anti-ligand antibody (black line) or the appropriate fluorochrome-conjugated isotype control antibody (grey line and fill). Data were analyzed using FCSalyzer software. For fusion protein binding studies, fusion proteins were added to either non-transfected CHO-S cells as a control (grey line and solid) or CHO-S transfectants expressing the corresponding ligands, incubated for 1 h at 6° C., washed, immunostained with Cy5-conjugated anti-human IgG-Fcγ specific antibody (black line), and analyzed by flow cytometry. See Figures 18-20. For CD16 binding studies, TIGIT or CD155 containing fusion proteins were incubated with either non-transfected CHO-S cells as a control (grey line and solid) or CD16-expressing CHO-S transfectants, and detection was performed by immunostaining using APC- or PE-conjugated antibodies recognizing TIGIT or CD155, respectively (black line). See Figure 21.
[0340] Example 2: Binding and mobility assays of fusion proteins Protein gel analysis Fusion proteins were separated on 12% SDS-PAGE gels with (R) or without (NR) reduction and stained in PageBlue protein stain (Thermo Scientific) for 12 hours. See Figure 22.
[0341] Immunoblot analysis Fusion proteins were then quantified by Pierce BCA Protein Assay Kit (Thermo Fisher) and loaded onto a 12% SDS-PAGE gel. Proteins were electrophoretically transferred onto Immobilon-P membrane (EMD Millipore, Billerica, MA) and incubated with (A) anti-PD1 primary antibody and (B) anti-IgG light chain primary antibody in Odyssey Blocking Buffer (Licor, Lincoln, NE) for 12 hours. Corresponding secondary antibodies (Santa Cruz) were used at a dilution of 1:10,000. Immunoblots were scanned using an Odyssey Infra Imaging System (LI-COR Biosciences, Model #9120). See Figure 23.
[0342] Fusion protein binding assay As shown in FIG. 24, CXCR4 / 7 and PD1+ melanoma cell lines, (A) YUMMER1.7 cells or (B) B16 cells, were incubated with the indicated fusion proteins for 1 hour at 6° C., then washed, immunostained using a Cy5-conjugated anti-human IgG-Fcγ specific antibody, and analyzed by flow cytometry (solid black line), and control samples were incubated without the fusion proteins (filled grey line).
[0343] Transwell assay The transwell inserts were inserted into a 24-well companion plate (Corning, Cat. No. 353504). The cell suspension was seeded into the upper cell invasion chamber at 25,000 cells / chamber. DMEM containing 100 ng / mL CXCL12 was added to each lower well as a chemoattractant. The samples were incubated at 37° C. for 24 hours to allow cell migration. A cotton swab was used to remove non-invaded cells on the apical surface of the insert, and 2% crystal violet was used to stain cells that had migrated to the underside of the support. See FIG. 25.
[0344] Example 3: TriTouch-101 induces melanoma regression. Tumor growth inhibition was induced by TriTouch-101 PD1hFcA*vMIPIICH-hFcB*CL(FP) in vivo. Using a B16F10 melanoma subcutaneous model, we demonstrated the induction of melanoma regression by PD1hFcA*vMIPIICH-hFcB*CL(FP). Briefly, 1×10 5 BL16 mice were treated with 100 μl (10 ug / mL) of FP (mouse R, mouse 2L, and mouse 2R) or PBS (mouse X or mouse L) for five times on days 13, 14, 15, 16, and 21 after subcutaneous inoculation of 16 B16F10 cells. Tumor size was measured (FIG. 26A). Representative images of one mouse from each treatment group (X in the upper panel and 2R in the lower panel) are shown in FIG. 26B. These in vivo data showing that TriTouch-101 induces melanoma regression are consistent with previous data showing that this fusion protein inhibits melanoma cells in migration assays (FIG. 25).
[0345] Example 4: NK regulates TriTouch protein species. ADCC was increased by the addition of multifunctional fusion proteins (Figure 27). SKOV-3 ovarian cell line was seeded at 3000 cells / well in 96-well plates, allowed to adhere, and labeled using Cell Tracker Red CMTPX reagent. The SKOV-3 cells were then labeled using green fluorescent caspase-3 reagent. CD16.NK-92 cell line (V158 mutant) was added to the wells at a 5:1 effector:target ratio with various fusion proteins at a concentration of 25mg / ml or without protein and analyzed by measuring the number of fluorescent double positive (red + green) cells using the Incucyte live cell analysis system. Results shown are from the 20 hour time point (Figure 27).
[0346] Other embodiments The recitation of multiple elements in a definition of a variable herein includes a definition of that variable as any single one of the recited elements or as a combination (or subcombination) of the recited elements. The recitation of an embodiment herein includes that embodiment as any single embodiment or in combination with any other embodiment or portion thereof.
[0347] The entire disclosure of each and every patent, patent application, and publication cited herein is incorporated herein by reference. Although the present invention has been disclosed with reference to specific embodiments, it is apparent that those skilled in the art may devise other embodiments and variations of the present invention without departing from the spirit and scope of the present invention. It is intended that the appended claims be construed to include all such embodiments and equivalent variations. The present invention includes the following aspects. <1> A fusion protein comprising component A and / or component B, Component A is Component Y, Component Z 2 , and component Z 3 and Component B is component X', component Z 2 ', and component Z 3 ', The fusion protein. <2> Component B is Component Z 1 ', which further includes <1> A fusion protein according to claim 1. <3> Component A is Component Z 1 Further comprising: <1> A fusion protein according to claim 1. <4> Further comprising component C, Component C is a component X and a component C L ', <1> ~ <3> A fusion protein according to any one of claims 1 to 4. <5> Further comprising component D, Component D is a component Q and a component C L Including, <1> ~ <4> A fusion protein according to any one of claims 1 to 4. <6> Component Y comprises a ligand domain, a receptor domain, an scFv domain, or a lipocalin domain; <1> ~ <5> A fusion protein according to any one of claims 1 to 4. <7> component Y comprises at least a portion of PD-1, CD112R, CD113, or MHC-I polypeptide-associated sequence A (MICA); <6> A fusion protein according to claim 1. <8> the fusion protein binds to PD-L1 or PD-L2; <7> A fusion protein according to claim 1. <9> Component X' comprises a virus-derived peptide, a ligand-derived peptide, a receptor-derived peptide, or an HTS-selected peptide; <1> A fusion protein according to claim 1. <10> Component X' comprises at least a portion of vMIP-II; <9> A fusion protein according to claim 1. <11> Component X' includes V1 or V1Δ; <10> A fusion protein according to claim 1. <12> Component X comprises a virus-derived peptide, a ligand-derived peptide, a receptor-derived peptide, or an HTS-selected peptide; <4> A fusion protein according to claim 1. <13> Component X comprises V1 or V1Δ; <12> A fusion protein according to claim 1. <14> the fusion protein binds to CXCR4; <9> ~ <13> A fusion protein according to any one of claims 1 to 4. <15> Component Y and Component Z 2 and are connected via a hinge. <1> A fusion protein according to claim 1. <16> Component Z 1 ' and component Z 2 ' and are connected via a hinge, <1> A fusion protein according to claim 1. <17> Component X' and Component Z 1 ' and are connected via a linker, <1> A fusion protein according to claim 1. <18> Component X and Component C L and are connected via a linker, <4> A fusion protein according to claim 1. <19> Component Q and Component C L and are connected via a linker, <5> A fusion protein according to claim 1. <20> the fusion protein binds to a receptor or ligand on an immune cell; <1> ~ <19> A fusion protein according to any one of claims 1 to 4. <21> the receptor is an Fc receptor; <20> A fusion protein according to claim 1. <22> Component X' comprises at least a portion of PD-1, TIGIT, CD96, CD112R, CD113, CD155, CD111, CD112, MHC-I polypeptide-related sequence A (MICA), NKG2A (CD94), MICB, ULBP1-5, TIM-3, CD226, NECL2, CRTAM, CD80, CTLA-4, KIR2DL1 / 2 / 3, or CD48; <1> ~ <21> A fusion protein according to any one of claims 1 to 4. <23> Component Y comprises at least a portion of PD-1, TIGIT, CD96, CD112R, CD113, CD155, CD111, CD112, MHC-I polypeptide-related sequence A (MICA), NKG2A (CD94), MICB, ULBP1-5, TIM-3, CD226, NECL2, CRTAM, CD80, CTLA-4, KIR2DL1 / 2 / 3, or CD48; <1> ~ <22> A fusion protein according to any one of claims 1 to 4. <24> Component X comprises at least a portion of PD-1, TIGIT, CD96, CD112R, CD113, CD155, CD111, CD112, MHC-I polypeptide-related sequence A (MICA), NKG2A (CD94), MICB, ULBP1-5, TIM-3, CD226, NECL2, CRTAM, CD80, CTLA-4, KIR2DL1 / 2 / 3, or CD48; <4> A fusion protein according to claim 1. <25> Component Q comprises at least a portion of PD-1, TIGIT, CD96, CD112R, CD113, CD155, CD111, CD112, MHC-I polypeptide-related sequence A (MICA), NKG2A (CD94), MICB, ULBP1-5, TIM-3, CD226, NECL2, CRTAM, CD80, CTLA-4, KIR2DL1 / 2 / 3, or CD48; <5> A fusion protein according to claim 1. <26> Component A comprises any one of the amino acid sequences of SEQ ID NO: 14 to SEQ ID NO: 22; <1> A fusion protein according to claim 1. <27> Component B comprises any one of the amino acid sequences of SEQ ID NO: 32 to SEQ ID NO: 35. <1> A fusion protein according to claim 1. <28> Component A comprises any one of the amino acid sequences of SEQ ID NO: 14 to SEQ ID NO: 22, and component B comprises any one of the amino acid sequences of SEQ ID NO: 32 to SEQ ID NO: 35. <1> A fusion protein according to claim 1. <29> Component B comprises any one of the amino acid sequences of SEQ ID NO: 49 to SEQ ID NO: 55; <1> A fusion protein according to claim 1. <30> Component C comprises any one of the amino acid sequences of SEQ ID NO: 57 to SEQ ID NO: 63; <1> A fusion protein according to claim 1. <31> Component B comprises any one of the amino acid sequences of SEQ ID NO: 49 to SEQ ID NO: 55, and component C comprises any one of the amino acid sequences of SEQ ID NO: 57 to SEQ ID NO: 63. <1> A fusion protein according to claim 1. <32> A fusion protein comprising component A, component B, and component C, Component A is Component Y, Component Z 2 , and component Z 3 Including, Component B is component X', component Z 2 ', and component Z 3 ', Component C is a component X and a component C' L Including, component Y comprises at least a portion of PD-1; Component Z 2 and component Z 2 ' comprises the CH2 domain of a human Fc, Component Z 3 and component Z 3 ' comprises the CH3 domain of a human Fc, Component X' and component X comprise at least a portion of vMIP-II; and Component C L 'comprises at least one CH1 domain of human IgG1κ, The fusion protein. <33> the fusion protein is capable of binding to (i) PD-L1 or PD-L2, (ii) CXCR4, and (iii) an Fc receptor or ligand on an immune cell; <32> A fusion protein according to claim 1. <34> Component A comprises the amino acid sequence of SEQ ID NO: 29 and component B comprises the amino acid sequence of SEQ ID NO: 30; <32> A fusion protein according to claim 1. <35> Component Y comprises the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:2; <32> A fusion protein according to claim 1. <36> Component Z 2 comprises the amino acid sequence of SEQ ID NO: 12, and / or the component Z 3 comprises the amino acid sequence of SEQ ID NO: 13; <32> A fusion protein according to claim 1. <37> Component A comprises the amino acid sequence of SEQ ID NO: 14 or SEQ ID NO: 15; <32> A fusion protein according to claim 1. <38> Component B comprises the amino acid sequence of SEQ ID NO: 49; <32> A fusion protein according to claim 1. <39> Component X' comprises the amino acid sequence of SEQ ID NO: 37; <32> A fusion protein according to claim 1. <40> Component Z 2 ' comprises SEQ ID NO: 12 and / or the component Z 3 ' comprises SEQ ID NO: 48, <32> A fusion protein according to claim 1. <41> Component X comprises the amino acid sequence of SEQ ID NO: 37; <32> A fusion protein according to claim 1. <42> Component C L ' comprises the amino acid sequence of SEQ ID NO: 64, <32> A fusion protein according to claim 1. <43> Component B comprises the amino acid sequence of SEQ ID NO: 53; <32> A fusion protein according to claim 1. <44> Component C comprises the amino acid sequence of SEQ ID NO: 61; <32> A fusion protein according to claim 1. <45> Component A comprises the amino acid sequence of SEQ ID NO: 14, component B comprises the amino acid sequence of SEQ ID NO: 53, and component C comprises the amino acid sequence of SEQ ID NO: 61; <32> A fusion protein according to claim 1. <46> A method for producing a fusion protein, comprising administering to a cell a first nucleic acid encoding human PD-1-hFcA, a second nucleic acid encoding vMIPII-CH'-hFcB, and a third nucleic acid encoding vMIPII-CL'. <47> the first nucleic acid encodes the amino acid sequence of SEQ ID NO: 14, and / or the second nucleic acid encodes the amino acid sequence of SEQ ID NO: 49, and / or the third nucleic acid encodes the amino acid sequence of SEQ ID NO: 57; <46> The method described above. <48> A pharma- ceutically acceptable carrier; <1> ~ <45> and a fusion protein according to any one of claims 1 to 4. <49> For patients who need treatment <1> ~ <45> 2. A method for treating a proliferative disorder in a patient comprising administering a therapeutically effective amount of the fusion protein of any one of claims 1 to 10. <50> wherein the proliferative disorder is cancer. <49> The method described above. <51> the cancer is a solid tumor; <50> The method described above. <52> The cancer is pancreatic cancer, breast cancer, ovarian cancer, bladder cancer, melanoma, glioblastoma, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), multiple myeloma, or colon cancer; <50> The method described above. <53> A fusion protein comprising the amino acid sequences of SEQ ID NO:14, SEQ ID NO:49, and SEQ ID NO:57.
Claims
1. A fusion protein comprising component A, component B, and component C, component A comprises an amino acid sequence selected from the group consisting of SEQ ID NO:14 to SEQ ID NO:15; component B comprises an amino acid sequence selected from the group consisting of SEQ ID NO:49 to SEQ ID NO:55; Component C comprises an amino acid sequence selected from the group consisting of SEQ ID NO:57 to SEQ ID NO:63; Component A is linked to component B via a disulfide bond, and component B is linked to component C via a disulfide bond; The fusion protein is capable of binding to (i) PD-L1, (ii) CXCR4, and (iii) an Fc receptor.
2. 2. The fusion protein of claim 1, wherein the fusion protein is capable of binding to (i) PD-L1 on a cancer cell, (ii) CXCR4 on the cancer cell, and (iii) an Fc receptor on an immune natural killer (NK) cell.
3. said component A comprising the amino acid sequence of SEQ ID NO: 14; said component B comprising the amino acid sequence of SEQ ID NO:49; said component C comprising the amino acid sequence of SEQ ID NO:57; A fusion protein according to claim 1 or claim 2.
4. said component A comprising the amino acid sequence of SEQ ID NO: 14; said component B comprising the amino acid sequence of SEQ ID NO:53; said component C comprising the amino acid sequence of SEQ ID NO:61; A fusion protein according to claim 1 or claim 2.
5. a first nucleic acid encoding said component A operably linked to a control element for directing expression of the first nucleic acid in a mammalian cell; a second nucleic acid encoding said component B operably linked to a control element for directing expression of the second nucleic acid in a mammalian cell; and a third nucleic acid encoding said component C operably linked to a control element for directing expression of the third nucleic acid in a mammalian cell; A nucleic acid system encoding a fusion protein according to any one of claims 1 to 4, comprising:
6. providing a mammalian cell in vitro with the nucleic acid system according to claim 5, culturing said mammalian cells after said providing; and purifying the fusion protein after said culturing. A method for producing the fusion protein according to any one of claims 1 to 4 in vitro, comprising:
7. The fusion protein of any one of claims 1 to 4 for use in the treatment of a proliferative disorder in a patient in need of such treatment.
8. The fusion protein of claim 7, wherein the proliferative disorder is cancer.
9. The fusion protein of claim 8, wherein the cancer is a solid tumor.
10. 9. The fusion protein of claim 8, wherein the cancer is pancreatic cancer, breast cancer, ovarian cancer, bladder cancer, melanoma, glioblastoma, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), multiple myeloma, or colon cancer.
11. The fusion protein of claim 8, wherein the cancer is melanoma.
Citation Information
Patent Citations
A novel peptidic antagonist of cxcr4 derived from the n-terminus of the viral chemokine vmip-ii
JP2003521521A
Single-specificity polypeptide reagents
JP2013511966A
Inhibition of CXCR4 Signaling in Cancer Immunotherapy
JP2016527303A
Treatment of cancer by combined blockade of pd-1 and cxcr4 signaling pathways
JP2018516969A
PD-l1 and PD-l2-based fusion proteins and uses thereof
WO2014121085A1
